# EDGAR Filing Document

**Accession Number:** 0000107140
**File Stem:** 0000107140-23-000034
**Filing Date:** 2023-3
**Character Count:** 218719
**Document Hash:** 5e843adfec60a4bb0d0084e56b384a22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000107140-23-000034.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0000107140-23-000034

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 88

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHN WILEY & SONS, INC.
- **CENTRAL INDEX KEY:** 0000107140
- **STANDARD INDUSTRIAL CLASSIFICATION:** BOOKS: PUBLISHING OR PUBLISHING AND PRINTING [2731]
- **IRS NUMBER:** 135593032
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11507
- **FILM NUMBER:** 23722837

**BUSINESS ADDRESS:**
- **STREET 1:** 111 RIVER STREET
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030
- **BUSINESS PHONE:** 2017486000

**MAIL ADDRESS:**
- **STREET 1:** 111 RIVER STREET
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WILEY JOHN & SONS, INC.
- **DATE OF NAME CHANGE:** 20070820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WILEY JOHN & SONS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" ? jwa-20230131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended January 31, 2023**

OR

□ **TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from_____ to _____

**Commission File No. 001-11507**

**JOHN WILEY & SONS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| New York | 13-5593032 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 111 River Street, Hoboken, New Jersey | 07030 |
| (Address of principal executive offices) | Zip Code |

---

 (201) 748-6000 <br> Registrant's telephone number, including area code

 Not Applicable <br> Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Class A Common Stock, par value $1.00 per share | WLY | New York Stock Exchange |
| Class B Common Stock, par value $1.00 per share | WLYB | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ⌧ | Accelerated filer □ |
| Non-accelerated filer □ | Smaller reporting company □ |
| | Emerging growth company □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

The number of shares outstanding of each of the Registrant's classes of common stock as of February 28, 2023 were:

Class A, par value $1.00 – 46,423,125

Class B, par value $1.00 – 9,026,395

------

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**INDEX**

---

| | | |
|:---|:---|:---|
| **PART I - FINANCIAL INFORMATION** | **PART I - FINANCIAL INFORMATION** | |
| [Item 1.](#ic0b42a4fbc1943749f60782842ce8f12_16) | [Financial Statements](#ic0b42a4fbc1943749f60782842ce8f12_16) | [5](#ic0b42a4fbc1943749f60782842ce8f12_16) |
|  | <u>[Condensed Consolidated Statements of Financial Position – Unaudited as of](#ic0b42a4fbc1943749f60782842ce8f12_19)[Janu](#ic0b42a4fbc1943749f60782842ce8f12_19)[ary](#ic0b42a4fbc1943749f60782842ce8f12_19)[, 202](#ic0b42a4fbc1943749f60782842ce8f12_19)[3](#ic0b42a4fbc1943749f60782842ce8f12_19)[and as of April 30, 2022](#ic0b42a4fbc1943749f60782842ce8f12_19)</u> | [5](#ic0b42a4fbc1943749f60782842ce8f12_19) |
|  | <u>[Condensed Consolidated Statements of Net](#ic0b42a4fbc1943749f60782842ce8f12_22)[(](#ic0b42a4fbc1943749f60782842ce8f12_22)[Loss)](#ic0b42a4fbc1943749f60782842ce8f12_22)[Income – Unaudited for the three and](#ic0b42a4fbc1943749f60782842ce8f12_22)[nine](#ic0b42a4fbc1943749f60782842ce8f12_22)[m](#ic0b42a4fbc1943749f60782842ce8f12_22)[onths ended](#ic0b42a4fbc1943749f60782842ce8f12_22)[January](#ic0b42a4fbc1943749f60782842ce8f12_22)[31, 202](#ic0b42a4fbc1943749f60782842ce8f12_22)[3](#ic0b42a4fbc1943749f60782842ce8f12_22)[and 202](#ic0b42a4fbc1943749f60782842ce8f12_22)[2](#ic0b42a4fbc1943749f60782842ce8f12_22)</u> | [6](#ic0b42a4fbc1943749f60782842ce8f12_22) |
|  | <u>[Condensed Consolidated Statements of Comprehensive](#ic0b42a4fbc1943749f60782842ce8f12_25)[(](#ic0b42a4fbc1943749f60782842ce8f12_25)[Loss)](#ic0b42a4fbc1943749f60782842ce8f12_25)[Income – Unaudited for the three and](#ic0b42a4fbc1943749f60782842ce8f12_25)[nine](#ic0b42a4fbc1943749f60782842ce8f12_25)[months ended](#ic0b42a4fbc1943749f60782842ce8f12_25)[January](#ic0b42a4fbc1943749f60782842ce8f12_25)[31, 202](#ic0b42a4fbc1943749f60782842ce8f12_25)[3](#ic0b42a4fbc1943749f60782842ce8f12_25)[and 202](#ic0b42a4fbc1943749f60782842ce8f12_25)[2](#ic0b42a4fbc1943749f60782842ce8f12_25)</u> | [7](#ic0b42a4fbc1943749f60782842ce8f12_25) |
|  | <u>[Condensed Consolidated Statements of Cash Flows – Unaudited for the](#ic0b42a4fbc1943749f60782842ce8f12_28)[nine](#ic0b42a4fbc1943749f60782842ce8f12_28)[months ended](#ic0b42a4fbc1943749f60782842ce8f12_28)[Jan](#ic0b42a4fbc1943749f60782842ce8f12_28)[uary](#ic0b42a4fbc1943749f60782842ce8f12_28)[31, 202](#ic0b42a4fbc1943749f60782842ce8f12_28)[3](#ic0b42a4fbc1943749f60782842ce8f12_28)[and 202](#ic0b42a4fbc1943749f60782842ce8f12_28)[2](#ic0b42a4fbc1943749f60782842ce8f12_28)</u> | [8](#ic0b42a4fbc1943749f60782842ce8f12_28) |
|  | <u>[Condensed Consolidated Statements of Shareholders' Equity – Unaudited for the three and](#ic0b42a4fbc1943749f60782842ce8f12_31)[nine](#ic0b42a4fbc1943749f60782842ce8f12_31)[months ended](#ic0b42a4fbc1943749f60782842ce8f12_31)[January](#ic0b42a4fbc1943749f60782842ce8f12_31)[31, 202](#ic0b42a4fbc1943749f60782842ce8f12_31)[3](#ic0b42a4fbc1943749f60782842ce8f12_31)[and 202](#ic0b42a4fbc1943749f60782842ce8f12_31)[2](#ic0b42a4fbc1943749f60782842ce8f12_31)</u> | [9](#ic0b42a4fbc1943749f60782842ce8f12_31) |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#ic0b42a4fbc1943749f60782842ce8f12_34) |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1. Basis of Presentation](#ic0b42a4fbc1943749f60782842ce8f12_37)</u> | [10](#ic0b42a4fbc1943749f60782842ce8f12_37) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 2. Recent Accounting Standards](#ic0b42a4fbc1943749f60782842ce8f12_40)</u> | [10](#ic0b42a4fbc1943749f60782842ce8f12_40) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 3. Acquisitions](#ic0b42a4fbc1943749f60782842ce8f12_43)</u> | [11](#ic0b42a4fbc1943749f60782842ce8f12_43) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 4. Revenue Recognition, Contracts with Customers](#ic0b42a4fbc1943749f60782842ce8f12_46)</u> | [13](#ic0b42a4fbc1943749f60782842ce8f12_46) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 5. Operating Leases](#ic0b42a4fbc1943749f60782842ce8f12_52)</u> | [17](#ic0b42a4fbc1943749f60782842ce8f12_52) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 6. Stock-Based Compensation](#ic0b42a4fbc1943749f60782842ce8f12_55)</u> | [19](#ic0b42a4fbc1943749f60782842ce8f12_55) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 7. Accumulated Other Comprehensive Loss](#ic0b42a4fbc1943749f60782842ce8f12_58)</u> | [20](#ic0b42a4fbc1943749f60782842ce8f12_58) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 8. Reconciliation of Weighted Average Shares Outstanding](#ic0b42a4fbc1943749f60782842ce8f12_61)</u> | [21](#ic0b42a4fbc1943749f60782842ce8f12_61) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 9. Restructuring and Related Charges (Credits)](#ic0b42a4fbc1943749f60782842ce8f12_64)</u> | [22](#ic0b42a4fbc1943749f60782842ce8f12_64) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 10. Segment Information](#ic0b42a4fbc1943749f60782842ce8f12_67)</u> | [26](#ic0b42a4fbc1943749f60782842ce8f12_67) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 11. Inventories](#ic0b42a4fbc1943749f60782842ce8f12_70)</u> | [28](#ic0b42a4fbc1943749f60782842ce8f12_70) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 12. Goodwill and Intangible Assets](#ic0b42a4fbc1943749f60782842ce8f12_73)</u> | [29](#ic0b42a4fbc1943749f60782842ce8f12_73) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 13. Income Taxes](#ic0b42a4fbc1943749f60782842ce8f12_76)</u> | [31](#ic0b42a4fbc1943749f60782842ce8f12_76) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 14. Retirement Plans](#ic0b42a4fbc1943749f60782842ce8f12_79)</u> | [32](#ic0b42a4fbc1943749f60782842ce8f12_79) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 15. Debt and Available Credit Facilities](#ic0b42a4fbc1943749f60782842ce8f12_82)</u> | [32](#ic0b42a4fbc1943749f60782842ce8f12_82) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 16. Derivative Instruments and Hedging Activities](#ic0b42a4fbc1943749f60782842ce8f12_85)</u> | [34](#ic0b42a4fbc1943749f60782842ce8f12_85) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 17. Capital Stock and Changes in Capital Accounts](#ic0b42a4fbc1943749f60782842ce8f12_88)</u> | [36](#ic0b42a4fbc1943749f60782842ce8f12_88) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 18. Commitments and Contingencies](#ic0b42a4fbc1943749f60782842ce8f12_91)</u> | [37](#ic0b42a4fbc1943749f60782842ce8f12_91) |
| [Item 2.](#ic0b42a4fbc1943749f60782842ce8f12_97) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ic0b42a4fbc1943749f60782842ce8f12_97)</u> | [38](#ic0b42a4fbc1943749f60782842ce8f12_97) |
| [Item 3.](#ic0b42a4fbc1943749f60782842ce8f12_112) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ic0b42a4fbc1943749f60782842ce8f12_112)</u> | [61](#ic0b42a4fbc1943749f60782842ce8f12_112) |
| [Item 4.](#ic0b42a4fbc1943749f60782842ce8f12_115) | <u>[Controls and Procedures](#ic0b42a4fbc1943749f60782842ce8f12_115)</u> | [62](#ic0b42a4fbc1943749f60782842ce8f12_115) |
| **[PART II - OTHER INFORMATION](#ic0b42a4fbc1943749f60782842ce8f12_118)** | **[PART II - OTHER INFORMATION](#ic0b42a4fbc1943749f60782842ce8f12_118)** |  |
| [Item 1.](#ic0b42a4fbc1943749f60782842ce8f12_121) | <u>[Legal Proceedings](#ic0b42a4fbc1943749f60782842ce8f12_121)</u> | [63](#ic0b42a4fbc1943749f60782842ce8f12_121) |
| [Item 1A.](#ic0b42a4fbc1943749f60782842ce8f12_124) | <u>[Risk Factors](#ic0b42a4fbc1943749f60782842ce8f12_124)</u> | [63](#ic0b42a4fbc1943749f60782842ce8f12_124) |
| [Item 2.](#ic0b42a4fbc1943749f60782842ce8f12_127) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#ic0b42a4fbc1943749f60782842ce8f12_127)</u> | [63](#ic0b42a4fbc1943749f60782842ce8f12_127) |
| [Item 6.](#ic0b42a4fbc1943749f60782842ce8f12_130) | <u>[Exhibits](#ic0b42a4fbc1943749f60782842ce8f12_130)</u> | [64](#ic0b42a4fbc1943749f60782842ce8f12_130) |
| **<u>[SIGNATURES](#ic0b42a4fbc1943749f60782842ce8f12_133)</u>** | **<u>[SIGNATURES](#ic0b42a4fbc1943749f60782842ce8f12_133)</u>** | [65](#ic0b42a4fbc1943749f60782842ce8f12_133) |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Cautionary Notice Regarding Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:**

This report contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 concerning our business, consolidated financial condition and results of operations. The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand a company's prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "anticipates," "believes," "plan," "assumes," "could," "should," "estimates," "expects," "intends," "potential," "seek," "predict," "may," "will" and similar references to future periods. All statements other than statements of historical facts included in this report regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding our fiscal year 2023 outlook, the anticipated impact on the ability of our employees, contractors, customers and other business partners to perform our and their respective responsibilities and obligations relative to the conduct of our business in the future due to the coronavirus (COVID-19) outbreak, anticipated restructuring charges and savings, operations, performance, and financial condition. Reliance should not be placed on forward-looking statements, as actual results may differ materially from those described in any forward-looking statements. Any such forward-looking statements are based upon many assumptions and estimates that are inherently subject to uncertainties and contingencies, many of which are beyond our control, and are subject to change based on many important factors. Such factors include, but are not limited to (i) the level of investment by Wiley in new technologies and products; (ii) subscriber renewal rates for our journals; (iii) the financial stability and liquidity of journal subscription agents; (iv) the consolidation of book wholesalers and retail accounts; (v) the market position and financial stability of key retailers; (vi) the seasonal nature of our educational business and the impact of the used book market; (vii) worldwide economic and political conditions; (viii) our ability to protect our copyrights and other intellectual property worldwide; (ix) our ability to successfully integrate acquired operations and realize expected opportunities; (x) the ability to realize operating savings over time and in fiscal year 2023 in connection with our multiyear Business Optimization Program and our Fiscal Year 2023 Restructuring Program; (xi) the impact of COVID-19 on our operations, performance, and financial condition; and (xii) other factors detailed from time to time in our filings with the SEC. We undertake no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Please refer to Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K and as revised and updated by our Quarterly Reports in Form 10-Q for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Non-GAAP Financial Measures:**

We present financial information that conforms to Generally Accepted Accounting Principles in the United States of America (US GAAP). We also present financial information that does not conform to US GAAP, which we refer to as non-GAAP.

In this report, we may present the following non-GAAP performance measures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Earnings Per Share (Adjusted EPS);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free Cash Flow less Product Development Spending;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Contribution to Profit and margin;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Operating Income and margin;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Income Before Taxes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Income Tax Provision;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Effective Tax Rate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• EBITDA, Adjusted EBITDA and margin;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic revenue; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results on a constant currency basis.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Management uses these non-GAAP performance measures as supplemental indicators of our operating performance and financial position as well as for internal reporting and forecasting purposes, when publicly providing our outlook, to evaluate our performance and calculate incentive compensation. We present these non-GAAP performance measures in addition to US GAAP financial results because we believe that these non-GAAP performance measures provide useful information to certain investors and financial analysts for operational trends and comparisons over time. The use of these non-GAAP performance measures may also provide a consistent basis to evaluate operating profitability and performance trends by excluding items that we do not consider to be controllable activities for this purpose.

The performance metric used by our chief operating decision maker to evaluate performance of our reportable segments is Adjusted Contribution to Profit. We present both Adjusted Contribution to Profit and Adjusted EBITDA for each of our reportable segments as we believe Adjusted EBITDA provides additional useful information to certain investors and financial analysts for operational trends and comparisons over time. It removes the impact of depreciation and amortization expense, as well as presents a consistent basis to evaluate operating profitability and compare our financial performance to that of our peer companies and competitors.

For example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EPS, Adjusted Contribution to Profit, Adjusted Operating Income, Adjusted Income Before Taxes, Adjusted Income Tax Provision, Adjusted Effective Tax Rate, Adjusted EBITDA, and organic revenue (excluding acquisitions) provide a more comparable basis to analyze operating results and earnings and are measures commonly used by shareholders to measure our performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free Cash Flow less Product Development Spending helps assess our ability, over the long term, to create value for our shareholders as it represents cash available to repay debt, pay common stock dividends, and fund share repurchases and acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results on a constant currency basis remove distortion from the effects of foreign currency movements to provide better comparability of our business trends from period to period. We measure our performance excluding the impact of foreign currency (or at constant currency), which means that we apply the same foreign currency exchange rates for the current and equivalent prior period.

In addition, we have historically provided these or similar non-GAAP performance measures and understand that some investors and financial analysts find this information helpful in analyzing our operating margins and net income, and in comparing our financial performance to that of our peer companies and competitors. Based on interactions with investors, we also believe that our non-GAAP performance measures are regarded as useful to our investors as supplemental to our US GAAP financial results, and that there is no confusion regarding the adjustments or our operating performance to our investors due to the comprehensive nature of our disclosures. We have not provided our 2023 outlook for the most directly comparable US GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with US GAAP.

Non-GAAP performance measures do not have standardized meanings prescribed by US GAAP and therefore may not be comparable to the calculation of similar measures used by other companies and should not be viewed as alternatives to measures of financial results under US GAAP. The adjusted metrics have limitations as analytical tools, and should not be considered in isolation from, or as a substitute for, US GAAP information. It does not purport to represent any similarly titled US GAAP information and is not an indicator of our performance under US GAAP. Non-GAAP financial metrics that we present may not be comparable with similarly titled measures used by others. Investors are cautioned against placing undue reliance on these non-GAAP measures.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION – UNAUDITED**

**In thousands**

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** |
| **Assets:** | | |
| Current assets |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $**126449** | $100397 |
| &nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $20.9 million and $21.2 million, respectively | **283654** | 331960 |
| &nbsp;&nbsp;Inventories, net | **33167** | 36585 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | **87896** | 81924 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | **531166** | 550866 |
| Technology, property and equipment, net | **248298** | 271572 |
| Intangible assets, net | **868267** | 931429 |
| Goodwill | **1203254** | 1302142 |
| Operating lease right-of-use assets | **94672** | 111719 |
| Other non-current assets | **204598** | 193967 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**3150255** | $3361695 |
| **Liabilities and shareholders' equity:** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;Accounts payable | $**32384** | $77438 |
| &nbsp;&nbsp;Accrued royalties | **154227** | 101596 |
| &nbsp;&nbsp;Short-term portion of long-term debt | **5000** | 18750 |
| &nbsp;&nbsp;Contract liabilities | **369250** | 538126 |
| &nbsp;&nbsp;Accrued employment costs | **81106** | 117121 |
| &nbsp;&nbsp;Short-term portion of operating lease liabilities | **20055** | 20576 |
| &nbsp;&nbsp;Other accrued liabilities | **98947** | 95812 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | **760969** | 969419 |
| Long-term debt | **940576** | 768277 |
| Accrued pension liability | **78283** | 78622 |
| Deferred income tax liabilities | **144602** | 180065 |
| Operating lease liabilities | **119803** | 132541 |
| Other long-term liabilities | **79122** | 90502 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **2123355** | 2219426 |
| **Shareholders' equity** |  |  |
| &nbsp;&nbsp;Preferred stock, $1 par value per share: Authorized shares – 2 million, Issued shares - 0 | **—** |  |
| &nbsp;&nbsp;Class A common stock, $1 par value per share: Authorized shares - 180 million, Issued shares - 70,228 and 70,226 as of January 31, 2023 and April 30, 2022, respectively | **70228** | 70226 |
| &nbsp;&nbsp;Class B common stock, $1 par value per share: Authorized shares - 72 million, Issued shares - 12,954 and 12,956 as of January 31, 2023 and April 30, 2022, respectively | **12954** | 12956 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | **469542** | 459297 |
| &nbsp;&nbsp;&nbsp;Retained earnings | **1811816** | 1921160 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss, net of tax | **(505537)** | (508146) |
| &nbsp;&nbsp;Less treasury shares at cost (Class A – 23,808 and 23,515 as of January 31, 2023 and April 30, 2022, respectively; Class B – 3,925 and 3,924 as of January 31, 2023 and April 30, 2022, respectively) | **(832103)** | (813224) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total shareholders' equity** | **1026900** | 1142269 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and shareholders' equity** | $**3150255** | $3361695 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF NET (LOSS) INCOME – UNAUDITED**

**Dollars in thousands except per share information**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| **Revenue, net** | $**491368** | $515884 | $**1493773** | $1537275 |
| **Costs and expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | **174051** | 172916 | **518384** | 513654 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating and administrative expenses | **255798** | 275475 | **791578** | 800254 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **99800** |  | **99800** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges (credits) | **8807** | 448 | **45204** | (1161) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | **19968** | 21056 | **65389** | 63683 |
| &nbsp;&nbsp;**Total costs and expenses** | **558424** | 469895 | **1520355** | 1376430 |
| **Operating (loss) income** | **(67056)** | 45989 | **(26582)** | 160845 |
| Interest expense | **(11521)** | (5103) | **(27185)** | (14739) |
| Foreign exchange transaction gains (losses) | **421** | (488) | **283** | (1488) |
| Gain on sale of certain assets | **—** |  | **—** | 3694 |
| Other income, net | **705** | 2821 | **976** | 9524 |
| **(Loss) income before taxes** | **(77451)** | 43219 | **(52508)** | 157836 |
| (Benefit) provision for income taxes | **(5982)** | 7853 | **(1397)** | 52673 |
| Net (loss) income | $**(71469)** | $35366 | $**(51111)** | $105163 |
| **(Loss) earnings per share** |  |  |  |  |
| &nbsp;&nbsp;Basic | $**(1.29)** | $0.63 | $**(0.92)** | $1.89 |
| &nbsp;&nbsp;Diluted | $**(1.29)** | $0.63 | $**(0.92)** | $1.86 |
| **Weighted average number of common shares outstanding** |  |  |  |  |
| &nbsp;&nbsp;Basic | **55514** | 55701 | **55625** | 55789 |
| &nbsp;&nbsp;Diluted | **55514** | 56389 | **55625** | 56481 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME – UNAUDITED**

**Dollars in thousands**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| **Net (loss) income** | $**(71469)** | $35366 | $**(51111)** | $105163 |
| **Other comprehensive income (loss):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | **50348** | (15918) | **(5580)** | (31338) |
| &nbsp;&nbsp;Unamortized retirement (costs) credits, net of tax benefit (expense) of $1,872, $(1328), $(1865), and $(2954), respectively | **(7456)** | 4688 | **5771** | 10342 |
| &nbsp;&nbsp;Unrealized (loss) gain on interest rate swaps, net of tax benefit (expense) of $740, $(678), $(1008) and $(1453), respectively | **(2443)** | 2000 | **2418** | 4347 |
| **Total other comprehensive income (loss)** | **40449** | (9230) | **2609** | (16649) |
| **Comprehensive (loss) income** | $**(31020)** | $26136 | $**(48502)** | $88514 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – UNAUDITED**

**Dollars in thousands**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **<u>Operating activities</u>** |  |  |
| Net (loss) income | $**(51111)** | $105163 |
| **Adjustments to reconcile net (loss) income to net cash provided by operating activities:** |  |  |
| &nbsp;&nbsp;Impairment of goodwill | **99800** |  |
| &nbsp;&nbsp;Amortization of intangible assets | **65389** | 63683 |
| &nbsp;&nbsp;Amortization of product development assets | **25175** | 26662 |
| &nbsp;&nbsp;Depreciation and amortization of technology, property and equipment | **72578** | 72139 |
| &nbsp;&nbsp;Restructuring and related charges (credits) | **45204** | (1161) |
| &nbsp;&nbsp;Stock-based compensation expense | **20613** | 19361 |
| &nbsp;&nbsp;Employee retirement plan expense | **22326** | 14309 |
| &nbsp;&nbsp;Foreign exchange transaction (gains) losses | **(283)** | 1488 |
| &nbsp;&nbsp;Gain on sale of certain assets | **(40)** | (3694) |
| &nbsp;&nbsp;Other noncash (credits) charges | **(16160)** | 39044 |
| &nbsp;&nbsp;Net change in operating assets and liabilities | **(229773)** | (178510) |
| &nbsp;&nbsp;**Net cash provided by operating activities** | **53718** | 158484 |
| **<u>Investing activities</u>** |  |  |
| &nbsp;&nbsp;Product development spending | **(17763)** | (20388) |
| &nbsp;&nbsp;Additions to technology, property and equipment | **(57616)** | (60668) |
| &nbsp;&nbsp;Businesses acquired in purchase transactions, net of cash acquired | **(5792)** | (70620) |
| &nbsp;&nbsp;Proceeds related to the sale of certain assets | **40** | 3375 |
| &nbsp;&nbsp;Acquisitions of publication rights and other | **1059** | (3750) |
| &nbsp;&nbsp;**Net cash used in investing activities** | **(80072)** | (152051) |
| **<u>Financing activities</u>** |  |  |
| &nbsp;&nbsp;Repayments of long-term debt | **(475576)** | (268466) |
| &nbsp;&nbsp;Borrowings of long-term debt | **637879** | 373800 |
| &nbsp;&nbsp;Payment of debt issuance costs | **(4493)** |  |
| &nbsp;&nbsp;Purchases of treasury shares | **(24000)** | (24867) |
| &nbsp;&nbsp;Change in book overdrafts | **(14990)** | (4000) |
| &nbsp;&nbsp;Cash dividends | **(58067)** | (57900) |
| &nbsp;&nbsp;Impact of tax withholding on stock-based compensation and other | **(5469)** | (5468) |
| &nbsp;&nbsp;**Net cash provided by financing activities** | **55284** | 13099 |
| **Effects of exchange rate changes on cash, cash equivalents, and restricted cash** | **(2670)** | (3875) |
| *Cash reconciliation:* |  |  |
| Cash and cash equivalents | **100397** | 93795 |
| Restricted cash included in Prepaid expenses and other current assets | **330** | 564 |
| &nbsp;&nbsp;&nbsp;**Balance at beginning of period** | **100727** | 94359 |
| &nbsp;&nbsp;&nbsp;**Increase for the period** | **26260** | 15657 |
| Cash and cash equivalents | **126449** | 109444 |
| Restricted cash included in Prepaid expenses and other current assets | **538** | 572 |
| &nbsp;&nbsp;&nbsp;**Balance at end of period** | $**126987** | $110016 |
| **Cash paid during the period for:** |  |  |
| &nbsp;&nbsp;&nbsp;Interest | $**25796** | $13601 |
| &nbsp;&nbsp;&nbsp;Income taxes, net of refunds | $**38816** | $34040 |
| &nbsp;&nbsp;&nbsp;**Noncash items:** |  |  |
| &nbsp;&nbsp;&nbsp;Shared issued in connection with the acquisition of a business | $**—** | $7363 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**JOHN WILEY & SONS, INC., AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY – UNAUDITED**

**Dollars in thousands**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Class A common stock** | **Class B common stock** | **Additional<br>paid-in capital** | **Retained<br>earnings** | **Accumulated other comprehensive loss, net of tax** | **Treasury stock** | **Total<br>shareholders' equity** |
| Balance at October 31, 2022 | $**70228** | $**12954** | $**465216** | $**1902661** | $**(545986)** | $**(827266)** | $**1077807** |
| Restricted shares issued under stock-based compensation plans | **—** | **—** | **(2432)** | **2** | **—** | **2506** | **76** |
| Impact of tax withholding on stock-based compensation and other | **—** | **—** | **137** | **—** | **—** | **(843)** | **(706)** |
| Stock-based compensation expense | **—** | **—** | **6621** | **—** | **—** | **—** | **6621** |
| Purchases of treasury shares | **—** | **—** | **—** | **—** | **—** | **(6500)** | **(6500)** |
| Class A common stock dividends ($0.3475 per share) | **—** | **—** | **—** | **(16240)** | **—** | **—** | **(16240)** |
| Class B common stock dividends ($0.3475 per share) | **—** | **—** | **—** | **(3138)** | **—** | **—** | **(3138)** |
| Comprehensive loss, net of tax | **—** | **—** | **—** | **(71469)** | **40449** | **—** | **(31020)** |
| **Balance at January 31, 2023** | $**70228** | $**12954** | $**469542** | $**1811816** | $**(505537)** | $**(832103)** | $**1026900** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Class A common stock** | **Class B common stock** | **Additional<br>paid-in capital** | **Retained<br>earnings** | **Accumulated other<br>comprehensive loss, net of tax** | **Treasury stock** | **Total<br>shareholders' equity** |
| Balance at October 31, 2021 | $70211 | $12971 | $451808 | $1881235 | $(498209) | $(811351) | $1106665 |
| Restricted shares issued under stock-based compensation plans |  |  | (944) | 1 |  | 1015 | 72 |
| Issuance of Class A common stock related to the acquisition of a business |  |  |  |  |  | 7363 | 7363 |
| Impact of tax withholding on stock-based compensation and other |  |  | 2 |  |  | (238) | (236) |
| Stock-based compensation expense |  |  | 6299 |  |  |  | 6299 |
| Purchases of treasury shares |  |  |  |  |  | (7500) | (7500) |
| Class A common stock dividends ($0.3450 per share) |  |  |  | (16162) |  |  | (16162) |
| Class B common stock dividends ($0.3450 per share) |  |  |  | (3119) |  |  | (3119) |
| Common stock class conversions | 7 | (7) |  |  |  |  |  |
| Comprehensive income, net of tax |  |  |  | 35366 | (9230) |  | 26136 |
| Balance at January 31, 2022 | $70218 | $12964 | $457165 | $1897321 | $(507439) | $(810711) | $1119518 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

**JOHN WILEY & SONS, INC., AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY – UNAUDITED**

**Dollars in thousands**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Class A common stock** | **Class B common stock** | **Additional<br>paid-in capital** | **Retained<br>earnings** | **Accumulated other comprehensive loss, net of tax** | **Treasury stock** | **Total<br>shareholders' equity** |
| Balance at April 30, 2022 | $**70226** | $**12956** | $**459297** | $**1921160** | $**(508146)** | $**(813224)** | $**1142269** |
| Restricted shares issued under stock-based compensation plans | **—** | **—** | **(10514)** | **3** | **—** | **10727** | **216** |
| Impact of tax withholding on stock-based compensation and other | **—** | **—** | **137** | **—** | **—** | **(5606)** | **(5469)** |
| Stock-based compensation expense | **—** | **—** | **20622** | **—** | **—** | **—** | **20622** |
| Purchases of treasury shares | **—** | **—** | **—** | **—** | **—** | **(24000)** | **(24000)** |
| Class A common stock dividends ($0.3475 per share) | **—** | **—** | **—** | **(48822)** | **—** | **—** | **(48822)** |
| Class B common stock dividends ($0.3475 per share) | **—** | **—** | **—** | **(9414)** | **—** | **—** | **(9414)** |
| Common stock class conversions | **2** | **(2)** | **—** | **—** | **—** | **—** | **—** |
| Comprehensive loss, net of tax | **—** | **—** | **—** | **(51111)** | **2609** | **—** | **(48502)** |
| **Balance at January 31, 2023** | $**70228** | $**12954** | $**469542** | $**1811816** | $**(505537)** | $**(832103)** | $**1026900** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Class A common stock** | **Class B common stock** | **Additional<br>paid-in capital** | **Retained<br>earnings** | **Accumulated other comprehensive loss, net of tax** | **Treasury stock** | **Total<br>shareholders' equity** |
| Balance at April 30, 2021 | $70208 | $12974 | $444358 | $1850058 | $(490790) | $(795517) | $1091291 |
| Restricted shares issued under stock-based compensation plans |  |  | (7920) |  |  | 8129 | 209 |
| Issuance of Class A common stock related to the acquisition of a business |  |  |  |  |  | 7363 | 7363 |
| Impact of tax withholding on stock-based compensation and other |  |  | 351 |  |  | (5819) | (5468) |
| Stock-based compensation expense |  |  | 20376 |  |  |  | 20376 |
| Purchases of treasury shares |  |  |  |  |  | (24867) | (24867) |
| Class A common stock dividends ($0.3450 per share) |  |  |  | (48537) |  |  | (48537) |
| Class B common stock dividends ($0.3450 per share) |  |  |  | (9363) |  |  | (9363) |
| Common stock class conversions | 10 | (10) |  |  |  |  |  |
| Comprehensive income, net of tax |  |  |  | 105163 | (16649) |  | 88514 |
| Balance at January 31, 2022 | $70218 | $12964 | $457165 | $1897321 | $(507439) | $(810711) | $1119518 |

---

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements**.**

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**JOHN WILEY & SONS, INC. AND SUBSIDIARIES**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1** — **Basis of Presentation**

Throughout this report, when we refer to "Wiley," the "Company," "we," "our," or "us," we are referring to John Wiley & Sons, Inc. and all our subsidiaries, except where the context indicates otherwise.

Our Unaudited Condensed Consolidated Financial Statements include all the accounts of the Company and our subsidiaries. We have eliminated all intercompany transactions and balances in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the Unaudited Condensed Consolidated Financial Condition, Results of Operations, Comprehensive Income and Cash Flows for the periods presented. Operating results for the interim period are not necessarily indicative of the results expected for the full year. All amounts are in thousands, except per share amounts, and approximate due to rounding. These financial statements should be read in conjunction with the most recent audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 30, 2022 as filed with the SEC on June 24, 2022 (2022 Form 10-K).

Our Unaudited Condensed Consolidated Financial Statements were prepared in accordance with the interim reporting requirements of the SEC. As permitted under those rules, annual footnotes or other financial information that are normally required by US GAAP have been condensed or omitted. The preparation of our Unaudited Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain prior year amounts have been reclassified to conform to the current year's presentation.

**Note 2** — **Recent Accounting Standards**

***Recently Adopted Accounting Standards***

Reference Rate Reform

In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting." In January 2021, the FASB clarified the scope of that guidance with the issuance of ASU 2021-01, "Reference Rate Reform: Scope." These ASUs provide optional guidance for a limited period of time to ease the burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This would apply to companies meeting certain criteria that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, "Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848," which extended the date to December 31, 2024. This standard was effective for us immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2024. On November 30, 2022, we amended the Amended and Restated CA (as defined in Note 15, "Debt and Available Credit Facilities") and as a result we amended our outstanding interest rate swaps designated as cash flow hedges to change the rates from LIBOR-based rates to SOFR-based rates. We applied ASU 2020-04 at the time of modification, and there was no impact on our Condensed Consolidated Financial Statements. The future impact of this ASU on our consolidated financial statements will be based on any future contract modifications.

Convertible Debt Instruments, Derivatives and EPS

In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40)". This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock, as well as amend the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related earnings-per-share (EPS) guidance. We adopted ASU 2020-06 on May 1, 2022. The adoption did not have an impact on our consolidated financial statements at the time of adoption.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Recently Issued Accounting Standards***

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". This ASU requires that an acquirer recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606 "Revenue from Contracts with Customers" (Topic 606) as if it had originated the contracts. Generally, this would result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree's financial statements if the acquiree prepared financial statements in accordance with US GAAP. This standard is effective for us on May 1, 2023, including interim periods within the fiscal year. Early adoption is permitted. The standard is applied prospectively to business combinations occurring on or after the effective date of the amendments. The impact will be based on future business combinations after we adopt the standard.

**Note 3** — **Acquisitions**

Pro forma financial information related to these acquisitions has not been provided as it is not material to our consolidated results of operations.

***Fiscal Year 2023***

On November 1, 2022, we completed the acquisition of an immaterial business included in our Academic segment. The fair value of consideration transferred was $6.1 million, which included $5.2 million of cash at the acquisition date and $0.9 million to be paid after the acquisition date. The acquisition was accounted for using the acquisition method of accounting. We recorded the preliminary aggregate excess purchase price over identifiable net tangible and intangible assets acquired and liabilities assumed, which included a preliminary allocation of $3.9 million of goodwill allocated to the Academic segment and $3.7 million of intangible assets subject to amortization.

The allocation of the total consideration transferred to the assets acquired, including intangible assets and goodwill, and the liabilities assumed could be revised as a result of additional information obtained due to tax related matters and contingencies and certain assets and liabilities, including receivables and payables, but such amounts will be finalized within the measurement period, which will not exceed one year from the acquisition date.

***Fiscal Year 2022***

XYZ Media

On December 29, 2021, we completed the acquisition of certain assets of XYZ Media Inc. (XYZ Media). XYZ Media is a company that generates leads for higher education institutions. The results of XYZ Media are included in our Academic segment results. The fair value of consideration transferred at the date of acquisition was $45.4 million which included $38.0 million of cash, and approximately 129 thousand shares of Wiley Class A common stock, or approximately $7.4 million. We financed the payment of the cash consideration with a combination of cash on hand and borrowings under our Amended and Restated CA (as defined below in Note 15, "Debt and Available Credit Facilities").

XYZ Media's incremental revenue and operating loss included in our Academic segment results for the three months ended January 31, 2023 was $1.5 million and $(0.8) million, respectively. XYZ Media's incremental revenue and operating loss included in our Academic segment results for the nine months ended January 31, 2023 was $6.9 million and $(3.1) million, respectively.

During the nine months ended January 31, 2023, no revisions were made to the allocation of the consideration transferred to the assets acquired and liabilities assumed. We recorded the fair value of the assets acquired and liabilities assumed on the acquisition date, which included an allocation of $22.2 million of goodwill allocated to the Academic segment and $22.7 million of intangible assets subject to amortization.

The allocation of the consideration transferred to the assets acquired and the liabilities assumed was finalized during the three months ended January 31, 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Other Acquisitions in Fiscal Year 2022

On November 30, 2021, we acquired the assets of the eJournalPress business (EJP) from Precision Computer Works, Inc. EJP is a technology platform company with an established journal submission and peer review management system. The results of EJP are included in our Research segment results.

On October 1, 2021, we completed the acquisition of certain assets of J&J Editorial Services, LLC. (J&J). J&J is a publishing services company providing expert offerings in editorial operations, production, copyediting, system support and consulting. The results of J&J are included in our Research segment results.

We also completed the acquisition of two immaterial businesses included in our Research segment and the acquisition of one immaterial business in our Talent segment.

The aggregate fair value of consideration transferred for these other acquisitions was approximately $41.2 million which included $36.2 million of cash paid at the acquisition dates and $5.0 million of additional cash to be paid after the acquisition dates. The fair value of the cash consideration transferred, net of $1.2 million of cash acquired was approximately $34.9 million. The fair value of the cash consideration transferred after the acquisition date that was paid during the nine months ended January 31, 2023 was $0.5 million.

The incremental revenue and operating loss included in the Research segment for the three months ended January 31, 2023 related to these other acquisitions was approximately $0.7 million and $(0.2) million, respectively. The incremental revenue and operating loss included in the Research segment for the nine months ended January 31, 2023 related to these other acquisitions was approximately $9.3 million and $(2.2) million, respectively.

During the nine months ended January 31, 2023, no revisions were made to the allocation of the consideration transferred to the assets acquired and liabilities assumed. Associated with these other acquisitions, we recorded the aggregate excess purchase price over identifiable net tangible and intangible assets acquired and liabilities assumed, which included an allocation of $24.8 million of goodwill allocated to the Research segment and $15.6 million of intangible assets subject to amortization. No goodwill was allocated to the Talent segment.

The allocation of the consideration transferred for the assets acquired, including intangible assets and goodwill, and liabilities assumed was finalized during the three months ended October 31, 2022 for the J&J acquisition and was finalized during the three months ended January 31, 2023 for EJP, and one of the other immaterial acquisitions in Research.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 4** — **Revenue Recognition, Contracts with Customers**

***Disaggregation of Revenue***

We have reorganized our Education lines of business into two new customer-centric segments. Our new segment reporting structure will consist of three reportable segments which includes Research (no changes), Academic, and Talent, as well as a Corporate expense category (no change), which includes certain costs that are not allocated to the reportable segments. Prior period segment results have been revised to the new segment presentation. There were no changes to our consolidated financial results. See Note 10, "Segment Information," for more details.

The following table presents our revenue from contracts with customers disaggregated by segment and product type.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| **Research:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research Publishing <sup>(1)</sup> | $**213720** | $224553 | $**685884** | $706690 |
| &nbsp;&nbsp;&nbsp;Research Solutions <sup>(1)</sup> | **39880** | 38788 | **113988** | 106561 |
| **Total Research** | **253600** | 263341 | **799872** | 813251 |
| **Academic:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Academic Publishing | **128564** | 143583 | **354728** | 400740 |
| &nbsp;&nbsp;&nbsp;University Services | **48951** | 55435 | **152892** | 169002 |
| **Total Academic** | **177515** | 199018 | **507620** | 569742 |
| **Talent** | **60253** | 53525 | **186281** | 154282 |
| **Total Revenue** | $**491368** | $515884 | $**1493773** | $1537275 |

---

(1) In May 2022 our revenue by product type previously referred to as Research Platforms was changed to Research Solutions. Research Solutions includes infrastructure and publishing services that help societies and corporations thrive in a complex knowledge ecosystem. In addition to Platforms (Atypon), certain product offerings such as corporate sales which included the recent acquisitions of Madgex Holdings Limited (Madgex), and Bio-Rad Laboratories Inc.'s Informatics products (Informatics) that were previously included in Research Publishing moved to Research Solutions to align with our strategic focus. Research Solutions also includes product offerings related to certain recent acquisitions such as J&J, and EJP. Prior period results have been revised to the new presentation. There were no changes to the total Research segment or our consolidated financial results. The revenue reclassified to Research Solutions was $24.3 million and $68.4 million for the three and nine months ended January 31, 2022, respectively.

The following information describes our disaggregation of revenue by segment and product type. Overall, the majority of our revenue is recognized over time.

**Research**

Research customers include academic, corporate, government, and public libraries, funders of research, researchers, scientists, clinicians, engineers and technologists, scholarly and professional societies, and students and professors. Research products are sold and distributed globally through multiple channels, including research libraries and library consortia, independent subscription agents, direct sales to researchers and professional society members, and other customers. Publishing centers include Australia, China, Germany, India, the United Kingdom (UK), and the United States (US). The majority of revenue generated from Research products is recognized over time. Total Research revenue was $253.6 million and $799.9 million in the three and nine months ended January 31, 2023, respectively.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

We disaggregated revenue by Research Publishing & Research Solutions to reflect the different type of products and services provided.

*<u>Research Publishing Products</u>*

Research Publishing products provide scientific, technical, medical, and scholarly journals, as well as related content and services, to academic, corporate, and government libraries, learned societies, and individual researchers and other professionals. Research Publishing revenue was $213.7 million and $685.9 million in the three and nine months ended January 31, 2023, respectively, and the majority is recognized over time.

Research Publishing products generate approximately 84% and 86% in the three and nine months ended January 31, 2023, respectively, of its revenue from contracts with its customers from Journal Subscriptions (pay to read), Open Access (pay to publish) and Transformational Agreements (read and publish) and the remainder from Licensing, Reprints, Backfiles, and Other.

*<u>Research Solutions Products and Services</u>*

Research Solutions services include Atypon Systems, Inc (Atypon) a publishing software and service provider that enables scholarly and professional societies and publishers to deliver, host, enhance, market, and manage their content on the web through the *Literatum* platform. In addition, Research Solutions includes advertising, spectroscopy software and spectral databases, and job board software and career center services, which includes the products and services from the recent acquisitions of Madgex and Informatics. As well as product and service offerings related to recent acquisitions such as J&J and the EJP business. J&J is a publishing services company providing expert offerings in editorial operations, production, copyediting, system support and consulting. EJP is a technology platform company with an established journal submission and peer-review management system. Research Solutions revenue was $39.9 million and $114.0 million in the three and nine months ended January 31, 2023, respectively, and the majority is recognized over time.

**Academic** 

Academic customers include chain and online booksellers, libraries, colleges and universities, corporations, direct to consumer, web sites, and other online applications. Total Academic revenue was $177.5 million and $507.6 million in the three and nine months ended January 31, 2023, respectively.

We disaggregated revenue by type of products provided. Academic products are Academic Publishing and University Services.

*<u>Academic Publishing Products</u>*

Academic Publishing products revenue was $128.6 million and $354.7 million in the three and nine months ended January 31, 2023, respectively. Products and services including scientific, professional, and education print and digital books, digital courseware, and test preparation services to libraries, corporations, students, professionals, and researchers. Communities served include business, finance, accounting, workplace learning, management, leadership, technology, behavioral health, engineering/architecture, science and medicine, and education. Products are developed for worldwide distribution through multiple channels, including chain and online booksellers, libraries, colleges and universities, corporations, direct to consumer, web sites, distributor networks and other online applications. Publishing centers include Australia, Germany, India, the UK, and the US.

Academic Publishing products generate approximately 65% and 69% in the three and nine months ended January 31, 2023, respectively, of its revenue from contracts with its customers for print and digital publishing, which is recognized at a point in time. Digital Courseware products generate approximately 21% and 17% of its revenue in the three and nine months ended January 31, 2023, respectively, which is recognized over time. The remainder of its revenues were from Test Preparation and Certification, and Licensing and Other, which has a mix of revenue recognized at a point in time and over time.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

*<u>University Services</u>*

University Services revenue was $49.0 million and $152.9 million in the three and nine months ended January 31, 2023, respectively, and is mainly recognized over time. University Services primarily engages in the comprehensive management of online degree programs for universities and has grown to include a broad array of technology enabled service offerings that address our partner specific pain points. Increasingly, this includes delivering career credentialing education that advances specific careers with in-demand skills.

**Talent**

Talent revenue was $60.3 million and $186.3 million in the three and nine months ended January 31, 2023, respectively. Services include sourcing, training, and preparing aspiring students and professionals to meet the skill needs of today's technology careers, and placing them with large companies and government agencies. Talent services works with its clients to retrain and retain existing employees so they can continue to meet the changing demands of today's technology landscape. This revenue is recognized at the point in time the services are provided to its customers.

Other services include high-demand soft-skills training solutions that are delivered to organizational clients through online digital delivery platforms, either directly or through an authorized distributor network of independent consultants, trainers, and coaches, as well as online learning and training solutions for global corporations, universities, and small and medium-sized enterprises sold on a subscription or fee basis. These digital learning solutions are either sold directly to corporate customers or through our global partners' network. This revenue is recognized mainly over time.

***Accounts Receivable, net and Contract Liability Balances***

When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue when, or as, control of the products or services are transferred to the customer and all revenue recognition criteria have been met.

The following table provides information about accounts receivable, net and contract liabilities from contracts with customers.

---

| | | | |
|:---|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** | **Increase/<br>(Decrease)** |
| Balances from contracts with customers: |  |  |  |
| &nbsp;&nbsp;Accounts receivable, net | $**283654** | $331960 | $(48306) |
| &nbsp;&nbsp;Contract liabilities <sup>(1)</sup> | **369250** | 538126 | (168876) |
| &nbsp;&nbsp;Contract liabilities (included in Other long-term liabilities) | $**18801** | $19072 | $(271) |

---

(1) The sales return reserve recorded in Contract liabilities is $28.0 million and $31.1 million, as of January 31, 2023 and April 30, 2022, respectively. 0

For the nine months ended January 31, 2023, we estimate that we recognized revenue of approximately 93% that was included in the current contract liability balance at April 30, 2022.

The decrease in contract liabilities excluding the sales return reserve, was primarily driven by revenue earned on journal subscription agreements, transformational agreements, and open access, partially offset by renewals of journal subscription agreements, transformational agreements, and open access.

***Remaining Performance Obligations included in Contract Liability***

As of January 31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations is approximately $388.0 million, which included the sales return reserve of $28.0 million. Excluding the sales return reserve, we expect that approximately $341.2 million will be recognized in the next twelve months with the remaining $18.8 million to be recognized thereafter.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Assets Recognized for the Costs to Fulfill a Contract***

Costs to fulfill a contract are directly related to a contract that will be used to satisfy a performance obligation in the future and are expected to be recovered. These costs are amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. These types of costs are incurred in the following product types, (1) Research Solutions services, which includes customer specific implementation costs per the terms of the contract and (2) University Services, which includes customer specific costs to develop courses per the terms of the contract.

Our assets associated with incremental costs to fulfill a contract were $10.5 million and $10.9 million at January 31, 2023 and April 30, 2022, respectively, and are included within Other non-current assets on our Unaudited Condensed Consolidated Statements of Financial Position. We recorded amortization expense of $1.1 million and $3.4 million during the three and nine months ended January 31, 2023, respectively, related to these assets within Cost of sales on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. We recorded amortization expense of $1.2 million and $4.0 million during the three and nine months ended January 31, 2022, respectively, related to these assets within Cost of sales on our Unaudited Condensed Consolidated Statements of Net (Loss) Income.

Sales and value-added taxes are excluded from revenues. Shipping and handling costs, which are primarily incurred within the Academic segment, occur before the transfer of control of the related goods. Therefore, in accordance with the revenue standard, it is not considered a promised service to the customer and would be considered a cost to fulfill our promise to transfer the goods. Costs incurred for third party shipping and handling are primarily reflected in Operating and administrative expenses on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. We incurred $7.1 million and $20.6 million in shipping and handling costs in the three and nine months ended January 31, 2023, respectively. We incurred $7.1 million and $21.1 million in shipping and handling costs in the three and nine months ended January 31, 2022, respectively.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 5** — **Operating Leases**

We have contractual obligations as a lessee with respect to offices, warehouses and distribution centers, automobiles, and office equipment.

We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the lease standard and we perform the lease classification test as of the lease commencement date. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.

The present value of the lease payments is calculated using an incremental borrowing rate, which was determined based on the rate of interest that we would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. We use an unsecured borrowing rate and risk-adjust that rate to approximate a collateralized rate.

Under the leasing standard, leases that are more than one year in duration are capitalized and recorded on our Unaudited Condensed Consolidated Statements of Financial Position. Some of our leases offer an option to extend the term of such leases. We utilize the reasonably certain threshold criteria in determining which options we will exercise. Furthermore, some of our lease payments are based on index rates with minimum annual increases. These represent fixed payments and are captured in the future minimum lease payments calculation.

For operating leases, the ROU assets and liabilities are presented on our Unaudited Condensed Consolidated Statement of Financial Position as follows:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** |
| Operating lease ROU assets | $**94672** | $111719 |
| Short-term portion of operating lease liabilities | **20055** | 20576 |
| Operating lease liabilities, non-current | $**119803** | $132541 |

---

During the nine months ended January 31, 2023, we added $2.6 million to the ROU assets and $2.4 million to the operating lease liabilities due to new leases, as well as modifications and remeasurements to our existing operating leases.

As a result of the Fiscal Year 2023 Restructuring Program, which included the exit of certain leased office space beginning in the three months ended July 31, 2022, we recorded restructuring charges. These charges included severance, impairment charges and acceleration of expense associated with certain operating lease ROU assets. See Note 9, "Restructuring and Related Charges (Credits)" for more information on this program and the charges incurred.

Our total net lease costs are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| Operating lease cost | $**4356** | $6015 | $**14066** | $18257 |
| Variable lease cost | **265** | 386 | **807** | 1127 |
| Short-term lease cost | **230** | 51 | **491** | 107 |
| Sublease income | **(198)** | (315) | **(568)** | (706) |
| Total net lease cost <sup>(1)</sup> | $**4653** | $6137 | $**14796** | $18785 |

---

(1) Total net lease cost does not include those costs and sublease income included in Restructuring and related charges (credits) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. This includes those operating leases we had identified as part of our restructuring programs that would be subleased. See Note 9, "Restructuring and Related Charges (Credits)" for more information on this program.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Other supplemental information includes the following:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| Weighted-average remaining contractual lease term (years) | **8** | 9 |
| Weighted-average discount rate | **5.93%** | 5.80% |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;Operating cash flows from operating leases | $**20264** | $22486 |

---

The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in our Unaudited Condensed Consolidated Statement of Financial Position as of January 31, 2023:

---

| | |
|:---|:---|
| **Fiscal Year** | **Operating Lease<br>Liabilities** |
| 2023 (remaining 3 months) | $7479 |
| 2024 | 26261 |
| 2025 | 24991 |
| 2026 | 23041 |
| 2027 | 18411 |
| Thereafter | 77853 |
| Total future undiscounted minimum lease payments | 178036 |
| &nbsp;&nbsp;Less: Imputed interest | 38178 |
| Present value of minimum lease payments | 139858 |
| &nbsp;&nbsp;Less: Current portion | 20055 |
| Noncurrent portion | $119803 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 6** — **Stock-Based Compensation**

We have stock-based compensation plans under which employees may be granted performance-based stock awards, other restricted stock awards and options. We recognize the grant date fair value of stock-based compensation in net income on a straight-line basis, net of estimated forfeitures over the requisite service period. The measurement of performance for performance-based stock awards is based on actual financial results for targets established up to three years in advance, or less. For the three and nine months ended January 31, 2023, we recognized stock-based compensation expense, on a pretax basis, of $6.6 million and $20.6 million, respectively. For the three and nine months ended January 31, 2022, we recognized stock-based compensation expense, on a pretax basis, of $6.3 million and $19.4 million, respectively.

***Performance-Based and Other Restricted Stock Activity***

Under the terms of our long-term incentive plans, performance-based restricted unit awards are payable in restricted shares of our Class A Common Stock upon the achievement of certain three-year or less financial performance-based targets. During each three-year period or less, we adjust compensation expense based upon our best estimate of expected performance.

We may also grant individual restricted unit awards payable in restricted shares of our Class A Common Stock to key employees in connection with their employment.

The following table summarizes awards we granted to employees (shares in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| Restricted Stock: |  |  |
| Awards granted (shares) | **546** | 653 |
| Weighted average fair value of grant | $**45.31** | $57.00 |

---

***Stock Option Activity***

We granted 10,000 and 290,000 stock option awards during the nine months ended January 31, 2023 and January 31, 2022, respectively. Options are exercisable over a maximum period of ten years from the date of grant. These options generally vest 10%, 20%, 30%, and 40% on April 30, or on each anniversary date after the award is granted.

The following table provides the estimated weighted average fair value for options granted during the nine months ended January 31, 2023 and 2022 using the Black-Scholes option-pricing model, and the significant weighted average assumptions used in their determination.

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| Weighted average fair value of options on grant date | $9.42 | $11.72 |
| Weighted average assumptions: |  |  |
| Expected life of options (years) | 5.9 | 6.3 |
| Risk-free interest rate | 0.5% | 1.2% |
| Expected volatility | 31.2% | 30.7% |
| Expected dividend yield | 3.0% | 2.4% |
| Fair value of common stock on grant date | $45.99 | $56.66 |
| Exercise price of stock option grant | $45.99 | $62.18 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 7** — **Accumulated Other Comprehensive Loss**

Changes in Accumulated other comprehensive loss by component, net of tax, for the three and nine months ended January 31, 2023 and 2022 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Foreign**<br>**Currency**<br>**Translation** | **Unamortized**<br>**Retirement**<br>**Costs** | **Interest**<br>**Rate Swaps** | **Total**  |
| **Balance at October 31, 2022** | $(385494) | $(168999) | $8507 | $(545986) |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 50348 | (8615) | (772) | 40961 |
| &nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss |  | 1159 | (1671) | (512) |
| &nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | 50348 | (7456) | (2443) | 40449 |
| **Balance at January 31, 2023** | $**(335146)** | $**(176455)** | $**6064** | $**(505537)** |
| **Balance at April 30, 2022** | $(329566) | $(182226) | $3646 | $(508146) |
| &nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (5580) | 2453 | 4295 | 1168 |
| &nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss |  | 3318 | (1877) | 1441 |
| &nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income | (5580) | 5771 | 2418 | 2609 |
| **Balance at January 31, 2023** | $**(335146)** | $**(176455)** | $**6064** | $**(505537)** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Foreign**<br>**Currency**<br>**Translation** | **Unamortized**<br>**Retirement**<br>**Costs** | **Interest**<br>**Rate Swaps** | **Total**  |
| **Balance at October 31, 2021** | $(273361) | $(222492) | $(2356) | $(498209) |
| &nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (15918) | 3275 | 1174 | (11469) |
| &nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss |  | 1413 | 826 | 2239 |
| &nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income | (15918) | 4688 | 2000 | (9230) |
| &nbsp;&nbsp;**Balance at January 31, 2022** | $(289279) | $(217804) | $(356) | $(507439) |
| **Balance at April 30, 2021** | $(257941) | $(228146) | $(4703) | $(490790) |
| &nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (31338) | 6056 | 1859 | (23423) |
| &nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss |  | 4286 | 2488 | 6774 |
| &nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income | (31338) | 10342 | 4347 | (16649) |
| **Balance at January 31, 2022** | $(289279) | $(217804) | $(356) | $(507439) |

---

During the three and nine months ended January 31, 2023, pretax actuarial losses included in Unamortized Retirement Costs of approximately $1.5 million and $4.4 million, respectively, and in the three and nine months ended January 31, 2022, of approximately $1.8 million and $5.5 million, respectively, were amortized from Accumulated other comprehensive loss and recognized as pension and post-retirement benefit expense primarily in Operating and administrative expenses and Other income, net on our Unaudited Condensed Consolidated Statements of Net (Loss) Income.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Our policy for releasing the income tax effects from accumulated other comprehensive (loss) income is to release when the corresponding pretax accumulated other comprehensive (loss) income items are reclassified to earnings.

**Note 8** — **Reconciliation of Weighted Average Shares Outstanding**

A reconciliation of the shares used in the computation of (loss) earnings per share follows (shares in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| Weighted average shares outstanding | **55514** | 55701 | **55625** | 55789 |
| **Shares used for basic (loss) earnings per share** | **55514** | 55701 | **55625** | 55789 |
| Dilutive effect of unvested restricted stock units and other stock awards | **—** | 688 | **—** | 692 |
| **Shares used for diluted (loss) earnings per share** | **55514** | 56389 | **55625** | 56481 |
| Antidilutive options to purchase Class A common shares, restricted shares, warrants to purchase Class A common shares, and contingently issuable restricted stock which are excluded from the table above | **1141** | 977 | **1155** | 863 |

---

In calculating diluted net loss per common share for the three and nine months ended January 31, 2023 our diluted weighted average number of common shares outstanding excludes the effect of unvested restricted stock units and other stock awards as the effect was anti-dilutive. This occurs when a net loss is reported and the effect of using dilutive shares is antidilutive.

The shares associated with performance-based stock awards ("PSUs") are considered contingently issuable shares and will be included in the diluted weighted average number of common shares outstanding when they have met the performance conditions, and when their effect is dilutive.

We included contingently issuable shares using the treasury stock method for certain PSUs in the diluted weighted average number of common shares outstanding based on the number of contingently issuable shares that would be issued assuming the end of our reporting period was the end of the relevant PSU contingency period. The calculation of diluted weighted average shares outstanding excluded these PSUs in the three and nine months ended January 31, 2023 as the effect was antidilutive as described above. The calculation of diluted weighted average shares outstanding related to these PSUs was nominal in the three and nine months ended January 31, 2022.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 9** — **Restructuring and Related Charges (Credits)**

***Fiscal Year 2023 Restructuring Program***

In May 2022, the Company initiated a global program to restructure and align our cost base with current and anticipated future market conditions (Fiscal Year 2023 Restructuring Program). This program includes severance related charges for the elimination of certain positions, the exit of certain leased office space, and the reduction of our occupancy at other facilities. We are reducing our real estate square footage occupancy by approximately 22%.

The following tables summarize the pretax restructuring charges related to this program:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2023** |
| Charges by Segment: |  |  |
| &nbsp;&nbsp;Research | $**319** | $1579 |
| &nbsp;&nbsp;Academic | **1823** | 10060 |
| &nbsp;&nbsp;Talent | **178** | 2514 |
| &nbsp;&nbsp;Corporate Expenses | **6540** | 30129 |
| Total Restructuring and Related Charges | $**8860** | $44282 |
| Charges by Activity: |  |  |
| &nbsp;&nbsp;Severance and termination benefits | $**7049** | $24613 |
| &nbsp;&nbsp;Impairment of operating lease ROU assets and property and equipment | **—** | 12696 |
| &nbsp;&nbsp;Acceleration of expense related to operating lease ROU assets and property and equipment | **152** | 1992 |
| &nbsp;&nbsp;Facility related charges, net | **706** | 3403 |
| &nbsp;&nbsp;Consulting costs | **167** | 597 |
| &nbsp;&nbsp;Other activities | **786** | 981 |
| &nbsp;&nbsp;Total Restructuring and Related Charges | $**8860** | $44282 |

---

The impairment charges of $12.7 million for the nine months ended January 31, 2023 included the impairment of operating lease ROU assets of $7.6 million related to certain leases that will be subleased, and the related property and equipment of $5.1 million described further below. These charges were recorded in corporate expenses.

The acceleration of expense of $2.0 million for the nine months ended January 31, 2023 included the acceleration of rent expense associated with operating lease ROU assets of $0.9 million related to certain leases that will be abandoned or terminated, and the related depreciation and amortization of property and equipment of $1.1 million.

Due to the actions taken above, we tested the operating lease ROU assets and the related property and equipment for those being subleased for recoverability by comparing the carrying value of the asset group to an estimate of the future undiscounted cash flows expected to result from the use and eventual disposition of the asset group. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset groups were below the carrying values. Therefore, there was an indication of impairment. We then determined the fair value of the asset groups by utilizing the present value of the estimated future cash flows attributable to the assets. The fair value of these operating lease ROU assets and the property and equipment immediately subsequent to the impairment was $12.1 million and was categorized as Level 3 within the FASB ASC Topic 820, "Fair Value Measurements" fair value hierarchy.

In addition, we also incurred ongoing facility-related costs associated with certain properties that resulted in additional restructuring charges of $0.7 million and $3.4 million in the three and nine months ended January 31, 2023, respectively. We also incurred consulting costs of $0.2 million and $0.6 million and other activities of $0.8 million and $1.0 million in the three and nine months ended January 31, 2023, respectively.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

In the three months ended January 31, 2023, due to the political instability and military actions between Russia and Ukraine, we made the decision to close our operations in Russia which primarily consists of technology development resources. We expect to be substantially completed by April 30, 2023, except for the liquidation of the operations in our fiscal year 2024. Included in the table above are restructuring charges for the three and nine months ended January 31, 2023 of $7.5 million, related to these actions, and include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Severance charges of $6.8 million for the elimination of certain positions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Relocation and other charges of $0.5 million primarily for positions that will remain with the Company but will be in another geographic location; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acceleration of depreciation and amortization of property and equipment of $0.2 million.

The following table summarizes the activity for the Fiscal Year 2023 Restructuring Program liability for the nine months ended January 31, 2023:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **April 30, 2022** | **Charges**  | **Payments**  | **Foreign**<br>**Translation**<br>**& Other Adjustments** | **January 31, 2023** |
| Severance and termination benefits | $— | $24613 | $(16157) | $222 | $**8678** |
| Consulting costs |  | 597 | (597) |  | **—** |
| Other activities |  | 981 | (814) | (60) | **107** |
| Total | $— | $26191 | $(17568) | $162 | $**8785** |

---

Approximately $7.8 million of the restructuring liability for accrued severance and termination benefits is reflected in Accrued employment costs and approximately $0.9 million is reflected in Other long-term liabilities on our Unaudited Condensed Consolidated Statement of Financial Position. The liability for Other activities is reflected in Other accrued liabilities.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Business Optimization Program***

Beginning in fiscal year 2020, we initiated a multiyear Business Optimization Program (the Business Optimization Program) to drive efficiency improvement and operating savings.

The following tables summarize the pretax restructuring (credits) charges related to this program:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Total Charges<br>Incurred to Date** |
| | **2023** | **2022** | **2023** | **2022** | **Total Charges<br>Incurred to Date** |
| (Credits) Charges by Segment: |  |  |  |  |  |
| &nbsp;&nbsp;Research | $**(2)** | $— | $**(2)** | $238 | $3880 |
| &nbsp;&nbsp;Academic | **28** | 261 | **31** | (347) | 12448 |
| &nbsp;&nbsp;Talent | **(106)** | (41) | **(114)** | 245 | 5032 |
| &nbsp;&nbsp;Corporate Expenses | **27** | 228 | **1007** | (1297) | 44397 |
| Total Restructuring and Related (Credits) Charges | $**(53)** | $448 | $**922** | $(1161) | $65757 |
| (Credits) Charges by Activity: |  |  |  |  |  |
| &nbsp;&nbsp;Severance and termination benefits | $**(238)** | $(291) | $**(225)** | $(2861) | $34894 |
| &nbsp;&nbsp;Impairment of operating lease ROU assets and property and equipment | **—** |  | **—** |  | 15079 |
| &nbsp;&nbsp;Acceleration of expense related to operating lease ROU assets and property and equipment | **—** |  | **—** |  | 3378 |
| &nbsp;&nbsp;Facility related charges, net | **185** | 739 | **1147** | 1700 | 10666 |
| &nbsp;&nbsp;Other activities | **—** |  | **—** |  | 1740 |
| Total Restructuring and Related (Credits) Charges | $**(53)** | $448 | $**922** | $(1161) | $65757 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

The credits in severance and termination benefits activities for the three and nine months ended January 31, 2023 and 2022 primarily reflects changes in the number of headcount reductions and estimates for previously accrued costs.

Facilities related charges, net include sublease income related to those operating leases we had identified in the year ended April 30, 2021 as part of our Business Optimization program that would be subleased.

The following table summarizes the activity for the Business Optimization Program liability for the nine months ended January 31, 2023:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **April 30, 2022** | **(Credits)** | **Payments**  | **Foreign**<br>**Translation**<br>**& Other Adjustments** | **January 31, 2023** |
| Severance and termination benefits | $2079 | $(225) | $(642) | $14 | $**1226** |
| Total | $2079 | $(225) | $(642) | $14 | $**1226** |

---

The restructuring liability for accrued severance and termination benefits is reflected in Accrued employment costs on our Unaudited Condensed Consolidated Statement of Financial Position as of January 31, 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 10** — **Segment Information**

We have reorganized our Education lines of business into two new customer-centric segments. The Academic segment addresses the university customer group and includes Academic Publishing and University Services. The Talent segment addresses the corporate customer group and will be focused on delivering training, sourcing, and upskilling solutions. Prior period segment results have been revised to the new segment presentation. There were no changes to our consolidated financial results. Our new segment reporting structure consists of three reportable segments, as well as a Corporate expense category (no change), which includes certain costs that are not allocated to the reportable segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Research, includes Research Publishing and Research Solutions, and no changes were made as a result of this realignment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Academic, includes the Academic Publishing and University Services lines. Academic Publishing is the combination of the former Education Publishing line and professional publishing offerings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Talent, is the combination of the former Talent Development line, and our corporate training and corporate learning offerings.

We report our segment information in accordance with the provisions of FASB Accounting Standards Codification (ASC) Topic 280, "Segment Reporting". These segments reflect the way our chief operating decision maker evaluates our business performance and manages the operations. The performance metric used by our chief operating decision maker to evaluate performance of our reportable segments is Adjusted Contribution to Profit.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Segment information is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| **Revenue**: |  |  |  |  |
| &nbsp;&nbsp;Research | $**253600** | $263341 | $**799872** | $813251 |
| &nbsp;&nbsp;Academic | **177515** | 199018 | **507620** | 569742 |
| &nbsp;&nbsp;Talent | **60253** | 53525 | **186281** | 154282 |
| Total revenue | $**491368** | $515884 | $**1493773** | $1537275 |
| **Adjusted Contribution to Profit:** |  |  |  |  |
| &nbsp;&nbsp;Research | $**57177** | $62165 | $**200739** | $218242 |
| &nbsp;&nbsp;Academic | **20988** | 31972 | **31492** | 68828 |
| &nbsp;&nbsp;Talent <sup>(1)</sup> | **5315** | 5676 | **24882** | 16615 |
| Total adjusted contribution to profit | **83480** | 99813 | **257113** | 303685 |
| Adjusted corporate contribution to profit | **(38258)** | (53376) | **(130426)** | (144001) |
| Total adjusted operating income | $**45222** | $46437 | $**126687** | $159684 |
| **Depreciation and Amortization:** |  |  |  |  |
| &nbsp;&nbsp;Research | $**23123** | $23914 | $**70308** | $71140 |
| &nbsp;&nbsp;Academic | **19922** | 19693 | **61547** | 61622 |
| &nbsp;&nbsp;Talent <sup>(1)</sup> | **5458** | 5605 | **19282** | 17304 |
| Total depreciation and amortization | **48503** | 49212 | **151137** | 150066 |
| Corporate depreciation and amortization | **3939** | 4151 | **12005** | 12418 |
| Total depreciation and amortization | $**52442** | $53363 | $**163142** | $162484 |

---

(1) On January 1, 2020, Wiley acquired mthree, a talent placement provider that addresses the IT skills gap by finding, training, and placing job-ready technology talent in roles with leading corporations worldwide. Its results of operations are included in our Talent segment. In late May 2022, Wiley renamed the mthree talent development solution to Wiley Edge and discontinued use of the mthree trademark during the three months ended July 31, 2022. As a result of these actions, we determined that a revision of the useful life was warranted and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022. This amortization expense was an adjustment to the Talent Adjusted contribution to profit. In addition, it was included in Depreciation and amortization in the table above for segment reporting.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

The following table shows a reconciliation of our consolidated US GAAP Operating (Loss) Income to Non-GAAP Adjusted Operating Income:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| **US GAAP Operating (Loss) Income** | $**(67056)** | $45989 | $**(26582)** | $160845 |
| Adjustments: |  |  |  |  |
| Restructuring and related charges (credits) <sup>(1)</sup> | 8807 | 448 | 45204 | (1161) |
| Impairment of goodwill <sup>(2)</sup> | 99800 |  | 99800 |  |
| Legal settlement <sup>(3)</sup> | 3671 |  | 3671 |  |
| Accelerated amortization of an intangible asset <sup>(4)</sup> |  |  | 4594 |  |
| **Non-GAAP Adjusted Operating Income** | $**45222** | $46437 | $**126687** | $159684 |

---

(1) See Note 9, "Restructuring and Related Charges (Credits)" for these charges by segment.

(2) See Note 12, "Goodwill and Intangible Assets" for these charges by segment.

(3) In the three months ended January 31, 2023, we settled a litigation matter related to consideration for a previous acquisition for $3.7 million which is included in our Corporate category.

(4) As described above, this accelerated amortization relates to the mthree trademark.

See Note 4, "Revenue Recognition, Contracts with Customers," for revenue from contracts with customers disaggregated by segment and product type for the three and nine months ended January 31, 2023 and 2022.

**Note 11** — **Inventories**

Inventories, net consisted of the following:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** |
| Finished goods | $**28546** | $31270 |
| Work-in-process | **1427** | 1729 |
| Paper and other materials | **325** | 275 |
| Total inventories before estimated sales returns and LIFO reserve | $**30298** | $33274 |
| Inventory value of estimated sales returns | **7378** | 7820 |
| LIFO reserve | **(4509)** | (4509) |
| Inventories, net | $**33167** | $36585 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 12** — **Goodwill and Intangible Assets**

***Goodwill***

The following table summarizes the activity in goodwill by segment as of January 31, 2023:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **April 30, 2022** <sup>(1)</sup> | **Acquisitions** <sup>(2)</sup> | **Impairment** | **Foreign Translation Adjustment**  | **January 31, 2023** |
| Research | $610416 | $— | $— | $(5132) | $**605284** |
| Academic | 442015 | 3878 | (99800) | (148) | **345945** |
| Talent | 249711 |  |  | 2314 | **252025** |
| Total | $1302142 | $3878 | $(99800) | $(2966) | $**1203254** |

---

(1) The Academic goodwill balance as of April 30, 2022 includes a cumulative pretax non-cash goodwill impairment of $110.0 million.

(2) Refer to Note 3, "Acquisitions," for more information related to the acquisition that occurred in the three months ended January 31, 2023.

*Change in Segment Reporting Structure and New Reporting Units*

We have reorganized our Education lines of business into two new customer-centric segments. Our new segment reporting structure will consist of three reportable segments which includes Research (no changes), Academic, and Talent, as well as a Corporate expense category (no change), which includes certain costs that are not allocated to the reportable segments. See Note 10, "Segment Information," for more details. The Academic reportable segment includes two reporting units, Academic Publishing and University Services, and the Talent reportable segment includes two reporting units, Talent Development and Professional Learning. No changes were made to the Research reportable segment.

Due to this realignment, we have reallocated goodwill as of April 30, 2022 to our reporting units.

As a result of this realignment, we are required to test goodwill for impairment immediately before and after the realignment. Since there were no changes to the Research reportable segment, no impairment test of the Research segment goodwill was required.

We estimated the fair value of the reporting units using a weighting of fair values derived from an income and a market approach. Under the income approach, we determined the fair value of a reporting unit based on the present value of estimated future cash flows. Cash flow projections are based on our best estimates of forecasted economic and market conditions over the period including growth rates, expected changes in operating cash flows and cash expenditures. The discount rate used is based on a weighted average cost of capital adjusted for the relevant risk associated with the characteristics of the business and the projected cash flows. The market approach estimates fair value based on market multiples of current and forward 12-month revenue or EBITDA, as applicable, derived from comparable publicly traded companies with similar operating and investment characteristics as the reporting unit.

*Goodwill Impairment Before Realignment*

Prior to the realignment, we concluded that the fair value of the Academic & Professional Learning reporting unit was above its carrying value. Therefore, there was no indication of impairment. The carrying value of the Education Services reporting unit was above its fair value which resulted in a pretax non-cash goodwill impairment of $31.0 million. This charge is reflected in Impairment of goodwill in the Unaudited Condensed Consolidated Statements of Net (Loss) Income.

Education Services was adversely impacted by market conditions and headwinds for online degree programs. This has led to a decline in projected student enrollments from existing partners, pricing pressures and revenue share concessions, and a decline in new partner additions over both the short-term and long-term, which adversely impacted forecasted revenue growth and operating cash flows. This was partially offset by projected growth in talent placements, partially due to expansion into new regions and the addition of new corporate clients, which are forecasted to have a positive impact on revenue growth and operating cash flows.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Prior to performing the goodwill impairment test for Education Services, we also evaluated the recoverability of long-lived assets of the reporting unit. The carrying value of the long-lived assets that were tested for impairment was approximately $467.0 million. When indicators of impairment are present, we test definite lived and long-lived assets for recoverability by comparing the carrying value of an asset group to an estimate of the future undiscounted cash flows expected to result from the use and eventual disposition of the asset group. We considered the lower-than-expected revenue and forecasted operating cash flows over a sustained period of time, and downward revisions to our cash flow forecasts for this reporting unit to be indicators of impairment for their long-lived assets. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group of the Education Services reporting unit exceeded the carrying value. Therefore, there was no impairment.

*Goodwill Impairment After Realignment*

After the realignment, we concluded that the fair value of the Academic Publishing, Talent Development and Professional Learning reporting units were above their carrying values. Therefore, there was no indication of impairment. The carrying value of the University Services reporting unit was above its fair value which resulted in a pretax non-cash goodwill impairment of $68.8 million. This charge is reflected in Impairment of goodwill in the Unaudited Condensed Consolidated Statements of Net (Loss) Income.

University Services was adversely impacted by market conditions and headwinds for online degree programs which lead to a decline in projected enrollments from existing partners, pricing pressures and revenue share concessions, and a decline in new partner additions over both the short-term and long-term which adversely impacted forecasted revenue growth and operating cash flows.

Prior to performing the goodwill impairment test for University Services, we also evaluated the recoverability of long-lived assets of the reporting unit. The carrying value of the long-lived assets that were tested for impairment was approximately $326.0 million. When indicators of impairment are present, we test definite lived and long-lived assets for recoverability by comparing the carrying value of an asset group to an estimate of the future undiscounted cash flows expected to result from the use and eventual disposition of the asset group. We considered the lower-than-expected revenue and forecasted operating cash flows over a sustained period of time, and downward revisions to our cash flow forecasts for this reporting unit to be indicators of impairment for their long-lived assets. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group of the University Services reporting unit exceeded the carrying value. Therefore, there was no impairment.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Intangible Assets***

Intangible assets, net were as follows:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022 ⁽¹⁾** |
| <u>Intangible assets with definite lives, net:</u> |  |  |
| Content and publishing rights | $**466190** | $499937 |
| Customer relationships | **223156** | 242058 |
| Developed technology | **48693** | 54721 |
| Brands and trademarks <sup>(2)</sup> | **9301** | 16021 |
| Covenants not to compete | **323** | 393 |
| Total intangible assets with definite lives, net | **747663** | 813130 |
| <u>Intangible assets with indefinite lives:</u> |  |  |
| Brands and trademarks | **37000** | 37000 |
| Publishing rights | **83604** | 81299 |
| Total intangible assets with indefinite lives | **120604** | 118299 |
| Total intangible assets, net | $**868267** | $931429 |

---

(1) The developed technology balance as of April 30, 2022 is presented net of accumulated impairments and write-offs of $2.8 million. The indefinite-lived brands and trademarks as of April 30, 2022 is net of accumulated impairments of $93.1 million.

(2) On January 1, 2020, Wiley acquired mthree, a talent placement provider that addresses the IT skills gap by finding, training, and placing job-ready technology talent in roles with leading corporations worldwide. Its results of operations are included in our Talent segment. In late May 2022, Wiley renamed the mthree talent development solution to Wiley Edge and discontinued use of the mthree trademark during the three months ended July 31, 2022. As a result of these actions, we determined that a revision of the useful life was warranted and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.

**Note 13** — **Income Taxes**

Our effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate for the three and nine months ended January 31, 2023, was 7.7% and 2.7%, respectively, compared with 18.2% and 33.4% for the three and nine months ended January 31, 2022, respectively.

The effective tax rate for the three months ended January 31, 2023, was lower than the US statutory rate primarily due to the impairment of goodwill resulting from the segment realignment described in Note 12, "Goodwill and Intangible Assets," and certain discrete items related to the filing of the consolidated US federal income tax return for the year ended April 30, 2022, as well as the geographic mix of earnings, the impact of US state taxes, and a discrete item relating to restricted stock compensation. The rate for the nine months ended January 31, 2023, was lower than the US statutory rate due to the same factors described above.

The effective tax rate for the three months ended January 31, 2023, was lower than the effective tax rate for the three months ended January 31, 2022, primarily due to the impairment of goodwill resulting from the segment realignment described in Note 12, "Goodwill and Intangible Assets," which results in a tax benefit of $4.8 million, and certain discrete items related to the filing of the consolidated US federal income tax return for the year ended April 30, 2022.

The effective tax rate for the nine months ended January 31, 2023, was lower than the effective tax rate for the nine months ended January 31, 2022, due to an increase in the UK statutory rate announced during the first three months of fiscal 2022 and reflected in the effective tax rate for the nine months ended January 31, 2022 as well as the factors described above. The UK enacted legislation on June 10, 2021, that increased its statutory rate from 19% to 25% effective April 1, 2023, resulting in a $20.7 million non-cash deferred tax expense.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Each year we file many tax returns given the number of national, state, and local tax jurisdictions in which we operate. These tax returns are subject to examination and possible challenge by the tax authorities, and positions challenged by the tax authorities may be settled or appealed by us. As a result, there is an uncertainty in income taxes recognized in our financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties, however, is not expected to have a material impact on the results of our operations.

**Note 14** — **Retirement Plans**

The components of net pension income for our defined benefit plans were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| Service cost | $**218** | $291 | $**610** | $898 |
| Interest cost | **6264** | 5122 | **18447** | 15523 |
| Expected return on plan assets | **(8281)** | (9986) | **(24703)** | (30387) |
| Amortization of prior service cost | **(23)** | (23) | **(70)** | (67) |
| Amortization of net actuarial loss | **1602** | 1858 | **4593** | 5632 |
| Net pension income | $**(220)** | $(2738) | $**(1123)** | $(8401) |

---

The service cost component of net pension income is reflected in Operating and administrative expenses on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. The other components of net pension income are reported separately from the service cost component and below Operating (loss) income. Such amounts are reflected in Other income, net on our Unaudited Condensed Consolidated Statements of Net (Loss) Income.

Employer defined benefit pension plan contributions were $3.6 million and $11.0 million for the three and nine months ended January 31, 2023, respectively, and $3.4 million and $11.9 million for the three and nine months ended January 31, 2022, respectively.

***Defined Contribution Savings Plans***

The expense for employer defined contribution savings plans was $7.9 million and $23.5 million for the three and nine months ended January 31, 2023, respectively, and $7.2 million and $22.8 million for the three and nine months ended January 31, 2022, respectively.

**Note 15** — **Debt and Available Credit Facilities**

Our total debt outstanding consisted of the amounts set forth in the following table:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** |
| Short-term portion of long-term debt <sup>(1)</sup> | $**5000** | $18750 |
| Term loan A - Amended and Restated CA <sup>(2)</sup> | **192966** | 204343 |
| Revolving credit facility - Amended and Restated CA | **747610** | 563934 |
| Total long-term debt, less current portion | **940576** | 768277 |
| Total debt | $**945576** | $787027 |

---

(1) Relates to our term loan A under the Amended and Restated CA.

(2) Amounts are shown net of unamortized issuance costs of $0.8 million as of January 31, 2023 and $0.3 million as of April 30, 2022.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Amended and Restated CA***

On November 30, 2022, we entered into the second amendment to the Third Amended and Restated Credit Agreement (collectively, the Amended and Restated CA). The Amended and Restated CA as of November 30, 2022 provided for senior unsecured credit facilities comprised of a (i) five-year revolving credit facility in an aggregate principal amount up to $1.115 billion, (ii) a five-year term loan A facility consisting of $200 million, and (iii) $185 million aggregate principal amount revolving credit facility through May 2024.

Under the terms of the Amended and Restated CA, which can be drawn in multiple currencies, we have the option of borrowing at the following floating interest rates depending on the currency borrowed: (i) at a rate based on the US Secured Overnight Financing Rate (SOFR), the Sterling Overnight Index Average Rate (SONIA) or a EURIBOR-based rate, each rate plus an applicable margin ranging from 0.98% to 1.50%, depending on our consolidated net leverage ratio, as defined, or (ii) at the lender's base rate plus an applicable margin ranging from zero to 0.50%, depending on our consolidated net leverage ratio. With respect to SOFR loans, there is a SOFR adjustment of between 0.10% and 0.25% depending on the duration of the loan. The lender's base rate is defined as the highest of (i) the US federal funds effective rate plus a 0.50% margin, (ii) the Daily SOFR rate, as defined, plus a 1.00% margin, or (iii) the Bank of America prime lending rate. In addition, we pay a facility fee for the Amended and Restated CA ranging from 0.15% to 0.25% depending on our consolidated net leverage ratio. We also have the option to request an increase in the revolving credit facility by an amount not to exceed $500 million, in minimum increments of $50 million, subject to the approval of the lenders.

The Amended and Restated CA contains certain customary affirmative and negative covenants, including a financial covenant in the form of a consolidated net leverage ratio and consolidated interest coverage ratio, which we were in compliance with as of January 31, 2023.

In the three months ended January 31, 2023, we incurred $4.5 million of costs related to the second amendment of the Amended and Restated CA which resulted in total costs capitalized of $5.8 million for the Amended and Restated CA. The amount related to the term loan A facility was $0.8 million, consisting of lender fees of $0.8 million recorded as a reduction to Long-term debt and non-lender fees of less than $0.1 million included in Other non-current assets on our Unaudited Condensed Consolidated Statement of Financial Position. The amount related to the revolving credit facility of which a portion matures in May 2024 and in November 2027 was $0.2 million and $4.8 million, respectively, all of which is included in Other non-current assets on our Unaudited Condensed Consolidated Statement of Financial Position.

We incurred a loss of $(0.2) million on the write-off of unamortized deferred costs in connection with the second amendment of the Amended and Restated CA which is reflected in Other income, net on our Unaudited Condensed Consolidated Statements of Net (Loss) Income in the three and nine months ended January 31, 2023.

The amortization expense of the costs incurred related to the Amended and Restated CA related to the lender and non-lender fees is recognized over a five-year term for credit commitments that mature in November 2027 and an 18-month term for credit commitments that mature in May 2024. Total amortization expense was $0.3 million and $0.8 million for the three and nine months ended January 31, 2023, respectively and is included in Interest expense on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. Total amortization expense was $0.3 million and $0.8 million for the three and nine months ended January 31, 2022, respectively and is included in Interest expense on our Unaudited Condensed Consolidated Statements of Net (Loss) Income.

As of January 31, 2023, we had approximately $553.4 million of unused borrowing capacity under our Amended and Restated CA and other facilities.

The weighted average interest rates on total debt outstanding during the three and nine months ended January 31, 2023 were 4.70% and 3.78%, respectively. The weighted average interest rates on total debt outstanding during the three and nine months ended January 31, 2022 were 1.94% and 1.96%, respectively. As of January 31, 2023 and April 30, 2022, the weighted average interest rates for total debt were 4.97% and 2.55%, respectively.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 16** — **Derivative Instruments and Hedging Activities**

From time-to-time, we enter into forward exchange and interest rate swap contracts as a hedge against foreign currency asset and liability commitments, changes in interest rates and anticipated transaction exposures, including intercompany sales and purchases. All derivatives are recognized as assets or liabilities and measured at fair value. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. We do not use financial instruments for trading or speculative purposes.

***Interest Rate Contracts***

As of January 31, 2023, we had total debt outstanding of $945.6 million, net of unamortized issuance costs of $0.8 million of which $946.4 million are variable rate loans outstanding under the Amended and Restated CA, which approximated fair value.

The following table summarizes our interest rate swaps designated as cash flow hedges:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Notional Amount** | **Notional Amount** | | |
|<br>**Hedged Item** <sup>(1)</sup> |<br>**Date entered into** |<br>**Nature of Swap** | **January 31, 2022** | **April 30, 2022** |<br>**Fixed Interest Rate** |<br>**Variable Interest Rate** |
| Amended and Restated CA | December 13, 2022 | Pay fixed/receive variable | $50 | $— | 3.772% | 1-month SOFR reset every month for a 3-year period ending December 15, 2025 |
| Amended and Restated CA | June 16, 2022 | Pay fixed/receive variable | $100 | $— | 3.467% | 1-month SOFR reset every month for a 3-year period ending May 15, 2024 <sup>(2)</sup> |
| Amended and Restated CA | April 12, 2021 | Pay fixed/receive variable | $100 | $100 | 0.465% | 1-month SOFR reset every month for a 3-year period ending April 15, 2024 <sup>(2)</sup> |
| Amended and Restated CA | April 6, 2022 | Pay fixed/receive variable | $100 | $100 | 2.588% | 1-month SOFR reset every month for a 2-year period ending April 15, 2024 <sup>(2)</sup> |
| Amended and Restated CA | February 26, 2020 | Pay fixed/receive variable | $100 | $100 | 1.168% | 1-month SOFR reset every month for a 3-year period ending March 15, 2023 <sup>(2)</sup> |
| Amended and Restated CA | August 7, 2019 | Pay fixed/receive variable | $— | $100 | 1.400% | 1-month LIBOR reset every month for a 3-year period ending August 15, 2022 |
| Amended and Restated CA | June 24, 2019 | Pay fixed/receive variable | $— | $100 | 1.650% | 1-month LIBOR reset every month for a 3-year period ending July 15, 2022 |
|  |  |  | $450 | $500 |  |  |

---

(1) On November 30, 2022, we entered into the Second Amendment to our Amended and Restated CA. Refer to Note 15, "Debt and Available Credit Facilities" for more information related to our Amended and Restated CA.

(2) On November 30, 2022, we amended the Amended and Restated CA (as defined in Note 15, "Debt and Available Credit Facilities") and as a result we amended our outstanding interest rate swaps designated as cash flow hedges to change the rates from LIBOR-based rates to SOFR-based rates. We applied ASU 2020-04 at the time of modification, and there was no impact on our Condensed Consolidated Financial Statements.

We record the fair value of our interest rate swaps on a recurring basis using Level 2 inputs of quoted prices for similar assets or liabilities in active markets. The fair value of the interest rate swaps as of January 31, 2023 was a deferred gain of $9.6 million. Based on the maturity dates of the contracts, $0.5 million of the deferred gain as of January 31, 2023 was recorded within Prepaid expenses and other current assets and $9.1 million of the deferred gain was recorded within Other non-current assets.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

The fair value of the interest rate swaps as of April 30, 2022 was a deferred loss of $(0.2) million and a deferred gain of $5.8 million. Based on the maturity dates of the contracts, the entire deferred loss as of April 30, 2022 was recorded within Other accrued liabilities, $0.9 million of the deferred gain was recorded within Prepaid expenses and other current assets, and $4.9 million was recorded within Other non-current assets.

The pretax gains that were reclassified from Accumulated other comprehensive loss into Interest expense for the three and nine months ended January 31, 2023 were $2.2 million and $2.5 million, respectively. The pretax (losses) that were reclassified from Accumulated other comprehensive loss into Interest expense for the three and nine months ended January 31, 2022 were $(1.1) million and $(3.3) million, respectively.

***Foreign Currency Contracts***

We may enter into forward exchange contracts to manage our exposure on certain foreign currency denominated assets and liabilities. The forward exchange contracts are marked to market through Foreign exchange transaction gains (losses) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income and carried at fair value on our Unaudited Condensed Consolidated Statements of Financial Position. Foreign currency denominated assets and liabilities are remeasured at spot rates in effect on the balance sheet date, with the effects of changes in spot rates reported in Foreign exchange transaction gains (losses) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income.

As of January 31, 2023, and April 30, 2022, we did not maintain any open forward exchange contracts. In addition, we did not maintain any open forward contracts during the nine months ended January 31, 2023 and 2022.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Note 17** — **Capital Stock and Changes in Capital Accounts**

***Share Repurchases***

The following table summarizes the share repurchases of Class A and Class B Common Stock (shares in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** | **2023** | **2022** |
| Shares repurchased - Class A | **157** | 134 | **539** | 446 |
| Shares repurchased - Class B | **1** | 1 | **1** | 2 |
| Average Price - Class A and Class B | $**41.14** | $55.40 | $**44.47** | $55.48 |

---

***Dividends***

The following table summarizes the cash dividends paid during the nine months ended January 31, 2023:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Date of Declaration by<br>Board of Directors** | **Quarterly Cash Dividend** | **Total Dividend** | **Class of Common Stock** | **Dividend Paid Date** | **Shareholders of<br>Record as of Date** |
| June 22, 2022 | $0.3475 per common share | $19.4 million | Class A and Class B | July 20, 2022 | July 6, 2022 |
| September 29, 2022 | $0.3475 per common share | $19.3 million | Class A and Class B | October 26, 2022 | October 11, 2022 |
| December 15, 2022 | $0.3475 per common share | $19.3 million | Class A and Class B | January 11, 2023 | December 27, 2022 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Changes in Common Stock***

The following is a summary of changes during the nine months ended January 31, in shares of our common stock and common stock in treasury (shares in thousands):

---

| | | |
|:---|:---|:---|
| **Changes in Common Stock A:** | **2023** | **2022** |
| **Number of shares, beginning of year** | **70226** | 70208 |
| Common stock class conversions | **2** | 10 |
| **Number of shares issued, end of period** | **70228** | 70218 |
| **Changes in Common Stock A in treasury:** |  |  |
| **Number of shares held, beginning of year** | **23515** | 23419 |
| Purchases of treasury shares | **539** | 446 |
| Restricted shares issued under stock-based compensation plans – non-PSU Awards | **(208)** | (163) |
| Restricted shares issued under stock-based compensation plans – PSU Awards | **(150)** | (108) |
| Shares issued under the Director Plan to Directors | **(3)** | (2) |
| Restricted shares issued from exercise of stock options | **(14)** | (24) |
| Shares issued related to the acquisition of a business | **—** | (129) |
| Shares withheld for taxes | **129** | 110 |
| **Number of shares held, end of period** | **23808** | 23549 |
| **Number of Common Stock A outstanding, end of period** | **46420** | 46669 |

---

---

| | | |
|:---|:---|:---|
| **Changes in Common Stock B:** | **2023** | **2022** |
| **Number of shares, beginning of year** | **12956** | 12974 |
| Common stock class conversions | **(2)** | (10) |
| **Number of shares issued, end of period** | **12954** | 12964 |
| **Changes in Common Stock B in treasury:** |  |  |
| **Number of shares held, beginning of year** | **3924** | 3922 |
| Purchase of treasury shares | **1** | 2 |
| **Number of shares held, end of period** | **3925** | 3924 |
| **Number of Common Stock B outstanding, end of period** | **9029** | 9040 |

---

**Note 18** — **Commitments and Contingencies**

We are involved in routine litigation in the ordinary course of our business. A provision for litigation is accrued when information available to us indicates that it is probable a liability has been incurred and the amount of loss can be reasonably estimated. Significant judgment may be required to determine both the probability and estimates of loss. When the amount of the loss can only be estimated within a range, the most likely outcome within that range is accrued. If no amount within the range is a better estimate than any other amount, the minimum amount within the range is accrued. When uncertainties exist related to the probable outcome of litigation and/or the amount or range of loss, we do not record a liability, but disclose facts related to the nature of the contingency and possible losses if management considers the information to be material. Reserves for legal defense costs are recognized when incurred. The accruals for loss contingencies and legal costs are reviewed regularly and may be adjusted to reflect updated information on the status of litigation and advice of legal counsel. In the opinion of management, the ultimate resolution of all pending litigation as of January 31, 2023, will not have a material effect on our consolidated financial condition or results of operations.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The information in our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read together with our Condensed Consolidated Financial Statements and related notes set forth in Item 1 of Part I of this Quarterly Report on Form 10-Q, our MD&A set forth in Item 7 of Part II of our 2022 Form 10-K and our Consolidated Financial Statements and related notes set forth in Item 8 of Part II of our 2022 Form 10-K. See Part II, Item 1A, "Risk Factors," below and "Cautionary Notice Regarding Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995," above, and the information referenced therein, for a description of risks that we face and important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. All amounts and percentages are approximate due to rounding and all dollars are in thousands, except per share amounts or where otherwise noted. When we cross-reference to a "Note," we are referring to our "Notes to Unaudited Condensed Consolidated Financial Statements," unless the context indicates otherwise.

**OVERVIEW**

Wiley is a global leader in scientific research and career-connected education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world's knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Wiley is a predominantly digital company with approximately 84% of revenue generated by digital products and tech-enabled services, and 56% of revenue is recurring, which includes revenue that is contractually obligated or set to recur with a high degree of certainty, for the nine months ended January 31, 2023.

We have reorganized our Education lines of business into two new customer-centric segments. The Academic segment addresses the university customer group and includes Academic Publishing and University Services. The Talent segment addresses the corporate customer group and will be focused on delivering training, sourcing, and upskilling solutions. Prior period segment results have been revised to the new segment presentation. There were no changes to our consolidated financial results. Our new segment reporting structure consists of three reportable segments, as well as a Corporate expense category (no change), which includes certain costs that are not allocated to the reportable segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Research, includes Research Publishing and Research Solutions, and no changes were made as a result of this realignment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Academic, includes the Academic Publishing and University Services lines. Academic Publishing is the combination of the former Education Publishing line and professional publishing offerings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Talent, is the combination of the former Talent Development line, and our corporate training and corporate learning offerings.

Through the Research segment, we provide peer-reviewed STM publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. The Academic segment provides scientific, professional, and education print and digital books, digital courseware, and test preparation services, as well as engages in the comprehensive management of online degree programs for universities. The Talent segment services include sourcing, training, and preparing aspiring students and professionals to meet the skill needs of today's technology careers, and placing them with large companies and government agencies. As well as corporate training and corporate learning offerings.

Wiley's business strategies are tightly aligned with accelerating growth trends, including open research, career-connected education, and talent development. Research strategies include driving publishing output to meet the global demand for peer-reviewed research and expanding platform and service offerings for corporations and societies. Education strategies include expanding online degree programs and driving online enrollment for university partners, scaling digital content and courseware, and expanding IT talent placement and reskilling programs for corporate partners.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**RESULTS OF OPERATIONS – THREE MONTHS ENDED JANUARY 31, 2023**

**<u>THIRD QUARTER SUMMARY:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **US GAAP Results**: Consolidated Revenue of $491.4 million (-5%, compared with the prior year), Operating Loss of $(67.1) million (compared with the prior year Operating Income of $46.0 million), and Diluted Loss per Share of $(1.29) (compared with the prior year Diluted Earnings per Share of $0.63). Losses primarily due to non-cash goodwill impairment in Education Services/University Services and restructuring charges.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Results** (at constant currency compared with the prior year): Consolidated Revenue of $491.4 million (-2%, compared with the prior year), Adjusted EBITDA of $97.7 million (-3%, compared with the prior year), and Adjusted EPS of $0.85 (-9%, compared with the prior year).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Fiscal 2023 Outlook:** Reduced to reflect increased Academic headwinds, and a publishing pause in a Hindawi special issues program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As a result of significant currency fluctuations, Wiley noted that Adjusted EBITDA in Research was being adversely impacted by Research royalty expenses denominated in British pounds but derived from US dollar revenues in our UK subsidiary. We have normalized for this foreign currency impact, resulting in a constant currency Adjusted EBITDA benefit of $2 million for the three months ended January 31, 2023 and an $8 million benefit for the nine months ended January 31, 2023. We have also amended our first and second quarters of fiscal year 2023 Adjusted EBITDA (+$3 million each quarter, respectively) for Research and Wiley overall to reflect the benefit for those periods. In the prior fiscal year, this impact was not significant. The Company believes this change will more adequately reflect Wiley's true operating performance.

**<u>CONSOLIDATED RESULTS OF OPERATIONS</u>**

**Revenue:**

Revenue for the three months ended January 31, 2023, decreased $24.5 million, or 5%, as compared with the prior year. On a constant currency basis, revenue decreased 2% as compared with prior year including contributions from acquisitions. Excluding the contributions from acquisitions, organic revenue decreased 3% on a constant currency basis.

See the "Segment Operating Results" below for additional details on each segment's revenue and Adjusted EBITDA performance.

**Cost of Sales:**

Cost of sales for the three months ended January 31, 2023, increased $1.1 million, or 1%, as compared with the prior year. On a constant currency basis, cost of sales increased 3% compared with the prior year. This was primarily due to higher employee costs to support the growth in placements in the Talent segment, partially offset by lower royalty costs.

**Operating and Administrative Expenses:**

Operating and administrative expenses for the three months ended January 31, 2023, decreased $19.7 million, or 7%, as compared with the prior year. On a constant currency basis, operating and administrative expenses decreased 4% as compared with the prior year primarily reflecting lower annual incentive compensation for fiscal year 2023, partially offset by a $3.7 million charge related to the settlement of a litigation matter related to consideration for a previous acquisition in the three months ended January 31, 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Impairment of Goodwill:**

We recorded an impairment of goodwill for the three months ended January 31, 2023 of $99.8 million. This charge is reflected in the Impairment of goodwill in the Unaudited Condensed Consolidated Statements of Net (Loss) Income.

In accordance with applicable accounting standards, we were required to test goodwill for impairment immediately before and after our segment realignment. Prior to the realignment, we concluded that the fair value of the Education Services reporting unit was below its carrying value, which resulted in a pretax non-cash goodwill impairment of $31.0 million. Education Services was adversely impacted by market conditions and headwinds for online degree programs. This has led to a decline in projected student enrollments from existing partners, pricing pressures and revenue share concessions, and a decline in new partner additions over both the short-term and long-term, which adversely impacted forecasted revenue growth and operating cash flows. This was partially offset by projected growth in talent placements, partially due to expansion into new regions and the addition of new corporate clients, which are forecasted to have a positive impact on revenue growth and operating cash flows.

After the realignment, we concluded that the fair value of the University Services reporting unit within the Academic segment was below its carrying value, which resulted in an additional pretax non-cash goodwill impairment of $68.8 million. University Services was adversely impacted by market conditions and headwinds for online degree programs, which lead to a decline in projected enrollments from existing partners, pricing pressures and revenue share concessions, and a decline in new partner additions over both the short-term and long-term which adversely impacted forecasted revenue growth and operating cash flows.

See Note 12, "Goodwill and Intangible Assets" for more details on these charges.

**Restructuring and Related Charges (Credits):**

***Fiscal Year 2023 Restructuring Program***

In May 2022, the Company initiated a global program to restructure and align our cost base with current and anticipated future market conditions. This program includes severance related charges for the elimination of certain position, the exit of certain leased office space which began in the first quarter of fiscal year 2023 and the reduction of our occupancy at other facilities. We are reducing our real estate square footage occupancy by approximately 22%. We anticipate $30 million in savings from actions starting in fiscal year 2023.

In the three months ended January 31, 2023, due to the political instability and military actions between Russia and Ukraine, we made the decision to close our operations in Russia, which primarily consists of technology development resources. We expect to be substantially completed by April 30, 2023 except for the liquidation of the operations in our fiscal year 2024.

For the three months ended January 31, 2023, we recorded pretax restructuring charges of $8.9 million related to this program, of which $7.5 million related to the closure of our operations in Russia as described above. This restructuring charge primarily reflects the following charges:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Severance charges of $7.0 million for the elimination of certain positions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acceleration of depreciation and amortization of property and equipment of $0.2 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consulting, relocation and other costs of $1.0 million; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ongoing facility-related costs with previously vacated properties that resulted in additional restructuring charges of $0.7 million.

These actions are anticipated to yield annualized cost savings estimated to be approximately $60 million. We anticipate ongoing facility-related costs associated with certain properties to result in additional restructuring charges in future periods.

These charges are reflected in Restructuring and related charges (credits) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. See Note 9, "Restructuring and Related Charges (Credits)" for more details on these charges.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Business Optimization Program***

For the three months ended January 31, 2023 and 2022, we recorded pretax restructuring credits of $0.1 million and charges of $0.4 million, respectively, related to this program. These charges and credits are reflected in Restructuring and related charges (credits) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. See Note 9, "Restructuring and Related Charges (Credits)" for more details on these charges and credits.

For the impact of our restructuring programs on diluted (loss) earnings per share, see the section below, "Diluted (Loss) Earnings per Share (EPS)."

**Amortization of Intangible Assets:**

Amortization of intangible assets was $20.0 million for the three months ended January 31, 2023, a decrease of $1.1 million, or 5%, as compared with the prior year. On a constant currency basis, amortization of intangible assets decreased 3% as compared with the prior year primarily due to the completion of amortization of certain acquired intangible assets, partially offset by the amortization of intangible assets related to the acquisitions completed in fiscal year 2022 and 2023. See Note 3, "Acquisitions" for more details on these acquisitions.

**Operating (Loss) Income, Adjusted Operating Income (OI) and Adjusted EBITDA:**

Operating loss was $(67.1) million for the three months ended January 31, 2023, compared with prior year operating income of $46.0 million. The decrease was primarily due to the impairment of goodwill in the three months ended January 31, 2023 and, to a lesser extent, the decrease in revenue, the increase in restructuring charges and, higher cost of sales, partially offset by a decrease in operating and administrative expenses as described above.

Adjusted OI and Adjusted EBITDA on a constant currency basis and excluding restructuring charges, impairment of goodwill and legal settlement decreased 6% and 3%, respectively, as compared with the prior year. The decrease in Adjusted OI and Adjusted EBITDA was primarily due to lower revenues and, to a lesser extent, higher cost of sales, partially offset by a decrease in operating and administrative expenses as described above.

***Adjusted Operating Income (OI)***

Below is a reconciliation of our consolidated US GAAP Operating (Loss) Income to Non-GAAP Adjusted OI:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP Operating (Loss) Income** | $**(67056)** | $45989 |
| Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | **8807** | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **99800** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement <sup>(1)</sup> | **3671** |  |
| **Non-GAAP Adjusted OI** | $**45222** | $46437 |

---

(1) In the three months ended January 31, 2023, we settled a litigation matter related to consideration for a previous acquisition for $3.7 million.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Adjusted EBITDA***

Below is a reconciliation of our consolidated US GAAP Net (Loss) Income to Non-GAAP EBITDA and Adjusted EBITDA:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **Net (Loss) Income** | $**(71469)** | $35366 |
| Interest expense | **11521** | 5103 |
| (Benefit) provision for income taxes | **(5982)** | 7853 |
| Depreciation and amortization | **52442** | 53363 |
| **Non-GAAP EBITDA** | **(13488)** | 101685 |
| Impairment of goodwill | **99800** |  |
| Legal settlement | **3671** |  |
| Restructuring and related charges | **8807** | 448 |
| Foreign exchange transaction (gains) losses | **(421)** | 488 |
| Other income, net | **(705)** | (2821) |
| **Non-GAAP Adjusted EBITDA** | $**97664** | $99800 |

---

**Interest Expense:**

Interest expense for the three months ended January 31, 2023, was $11.5 million compared with the prior year of $5.1 million. This increase was primarily due to a higher weighted average effective interest rate.

**Foreign Exchange Transaction Gains (Losses):**

Foreign exchange transaction gains of $0.4 million for the three months ended January 31, 2023 were primarily due to gains on our foreign currency denominated intercompany accounts receivable and payables balances, partially offset by losses on our third party accounts receivable and payable balances due to the impact of the change in average foreign exchange rates as compared to the US dollar.

Foreign exchange transaction losses of $(0.5) million for the three months ended January 31, 2022 were primarily due to losses on our foreign currency denominated intercompany and, to a lesser extent, third party accounts receivable and payable balances due to the impact of the change in average foreign exchange rates as compared to the US dollar.

**(Benefit) Provision for Income Taxes:**

Below is a reconciliation of our US GAAP (Loss) Income Before Taxes to Non-GAAP Adjusted Income Before Taxes:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP (Loss) Income Before Taxes** | $**(77451)** | $43219 |
| Pretax Impact of Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **99800** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **3671** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | **8807** | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gains) losses on intercompany transactions | **(2414)** | 722 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **21042** | 22189 |
| **Non-GAAP Adjusted Income Before Taxes** | $**53455** | $66578 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Below is a reconciliation of our US GAAP Income Tax (Benefit) Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP Income Tax (Benefit) Provision** | $**(5982)** | $7853 |
| Income Tax Impact of Adjustments <sup>(1)</sup>: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **4857** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **716** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | **2221** | 114 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange (gains) losses on intercompany transactions | **(596)** | 239 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **4591** | 4834 |
| **Non-GAAP Adjusted Income Tax Provision** | $**5807** | $13040 |
| **US GAAP Effective Tax Rate** | **7.7%** | 18.2% |
| **Non-GAAP Adjusted Effective Tax Rate** | **10.9%** | 19.6% |

---

(1) For the three months ended January 31, 2023, the tax impact was $4.0 million from current taxes and $7.8 million from deferred taxes. For the three months ended January 31, 2022, substantially all of the tax impact was from deferred taxes.

Our effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The US GAAP effective tax rate for the three months ended January 31, 2023, was 7.7% compared to 18.2% for the three months ended January 31, 2022. The US GAAP effective tax rate for the three months ended January 31, 2023, was lower than the US GAAP effective tax rate for the three months ended January 31, 2022, after taking into account certain discrete items realized related to the filing of the consolidated US federal income tax return for the year ended April 30, 2022, the tax impact on the impairment of goodwill, as well as the geographic mix of earnings, the impact of US state taxes, and a discrete item relating to restricted stock compensation.

Excluding the tax impact of the impairment of goodwill, restructuring and other adjustments noted in the table above, the Non-GAAP adjusted effective tax rate was 10.9% for the three months ended January 31, 2023, compared to 19.6% for the three months ended January 31, 2022. The reduction in the Non-GAAP adjusted effective tax rate for the three months ended January 31, 2023, compared with the prior year ended January 31, 2022, was primarily due to the same factors described above.

**Diluted (Loss) Earnings per Share (EPS):**

EPS for the three months ended January 31, 2023 was a loss of $(1.29) per share compared with earnings of $0.63 per share for the three months ended January 31, 2022. This decrease was due to an operating loss in the three months ended January 31, 2023, partially offset by an income tax benefit in the three months ended January 31, 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Below is a reconciliation of our US GAAP (Loss) Earnings Per Share to Non-GAAP Adjusted EPS. The amount of the pretax, and the related income tax impact for the adjustments included in the table below, are presented in the section above, "(Benefit) Provision for Income Taxes".

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP (Loss) Earnings Per Share** | $**(1.29)** | $0.63 |
| <u>Adjustments:</u> |  |  |
| &nbsp;&nbsp;&nbsp;Impairment of goodwill | **1.69** |  |
| &nbsp;&nbsp;&nbsp;Legal settlement | **0.05** |  |
| &nbsp;&nbsp;&nbsp;Restructuring and related charges | **0.12** | 0.01 |
| &nbsp;&nbsp;&nbsp;Foreign exchange (gains) losses on intercompany transactions | **(0.03)** | 0.01 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **0.29** | 0.30 |
| &nbsp;&nbsp;&nbsp;EPS impact of using weighted-average dilutive shares for adjusted EPS calculation <sup>(1)</sup> | **0.02** |  |
| **Non-GAAP Adjusted EPS** | $**0.85** | $0.95 |

---

(1) Represents the impact of using diluted weighted-average number of common shares outstanding (56.1 million shares for the three months ended January 31, 2023) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive.

On a constant currency basis, Adjusted EPS decreased 9% primarily due to higher interest expense and, to a lesser extent, a decrease in Adjusted Operating Income and lower pension credits, partially offset by lower income tax expense.

**<u>SEGMENT OPERATING RESULTS</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **RESEARCH** | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
|  | **2023** | **2022** | **2022** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **Revenue:** |  |  |  |  |  |
| Research Publishing <sup>(1)</sup> | **213720** | $| 224553 | (5)% | (3)% |
| Research Solutions <sup>(1)</sup> | **39880** | 38788 | 38788 | 3% | 6% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Research Revenue** | **253600** | 263341 | 263341 | (4)% | (1)% |
| Cost of Sales | **70806** | 72037 | 72037 | 2% | —% |
| Operating Expenses | **114045** | 117160 | 117160 | 3% | (2)% |
| Amortization of Intangible Assets | **11572** | 11979 | 11979 | 3% | —% |
| Restructuring Charges (see Note 9) | **317** |  |  | # | # |
| **Contribution to Profit** | **56860** | 62165 | 62165 | (9)% | (10)% |
| Restructuring Charges (see Note 9) | **317** |  |  | # | # |
| **Adjusted Contribution to Profit** | **57177** | 62165 | 62165 | (8)% | (9)% |
| Depreciation and amortization | **23123** | 23914 | 23914 | 3% | 1% |
| **Adjusted EBITDA** | **80300** | $| 86079 | (7)% | (7)% |
| Adjusted EBITDA Margin | **31.7%** | 32.7% | 32.7% |  |  |

---

# Not meaningful

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

(1) As previously announced in May 2022, our revenue by product type previously referred to as Research Platforms was changed to Research Solutions. Research Solutions includes infrastructure and publishing services that help societies and corporations thrive in a complex knowledge ecosystem. In addition to Platforms (Atypon), certain product offerings such as corporate sales which included the recent acquisitions of Madgex Holdings Limited (Madgex), and Bio-Rad Laboratories Inc.'s Informatics products (Informatics) that were previously included in Research Publishing moved to Research Solutions to align with our strategic focus. Research Solutions also includes product offerings related to certain recent acquisitions such as J&J, and EJP. Prior period results have been revised to the new presentation. There were no changes to the total Research segment or our consolidated financial results. The revenue reclassified was $24.3 million for the three months ended January 31, 2022, $93.3 million for the year ended April 30, 2022, and $80.3 million for the year ended April 30, 2021.

**Revenue:**

Research revenue for the three months ended January 31, 2023 decreased $9.7 million, or 4%, as compared with the prior year on a reported basis. On a constant currency basis, revenue decreased 1% as compared with the prior year. Excluding revenue from acquisitions, organic revenue decreased 2% on a constant currency basis primarily due to a pause in the Hindawi special issues publishing program. The program was suspended temporarily due to the presence in certain special issues of compromised articles. As a result, Hindawi revenue for the three months ended January 31, 2023 decreased $9 million on a constant currency basis as compared with the prior year, offsetting growth in other open access publishing programs. We have retracted hundreds of articles and the investigation is ongoing. We expect some impact on Hindawi submissions and publications in fiscal year 2024 due to the article backlog that has accumulated and the potential impact on Hindawi journal brands. Excluding Hindawi, Wiley's Research revenue for the three months ended January 31, 2023 on a constant currency basis increased 2% as compared with the prior year. Open access article output decreased approximately 25% for the three months ended January 31, 2023, as compared with the prior year. Excluding Hindawi, open access article output growth was approximately 17% for the three months ended January 31, 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA decreased 7% as compared with the prior year. This decrease was primarily due to revenue performance and, to a lesser extent, technology investment.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **ACADEMIC:** | **2023** | **2022** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **Revenue:** |  |  |  |  |
| Academic Publishing | **128564** | 143583 | (10)% | (8)% |
| University Services | **48951** | 55435 | (12)% | (11)% |
| &nbsp;&nbsp;&nbsp;**Total Academic Revenue** | **177515** | 199018 | (11)% | (9)% |
| Cost of Sales | **72920** | 76995 | 5% | 4% |
| Operating Expenses | **78424** | 83946 | 7% | 4% |
| Impairment of Goodwill (see Note 12) | **99800** |  | # | # |
| Amortization of Intangible Assets | **5183** | 6105 | 15% | 15% |
| Restructuring Charges (see Note 9) | **1851** | 261 | # | # |
| **Contribution to Profit** | **(80663)** | 31711 | # | # |
| Restructuring Charges (see Note 9) | **1851** | 261 | # | # |
| Impairment of Goodwill (see Note 12) | **99800** |  | # | # |
| **Adjusted Contribution to Profit** | **20988** | 31972 | (34)% | (34)% |
| Depreciation and amortization | **19922** | 19693 | (1)% | (2)% |
| **Adjusted EBITDA** | **40910** | 51665 | (21)% | (20)% |
| Adjusted EBITDA Margin | **23.0%** | 26.0% |  |  |

---

# Not meaningful

**Revenue:**

Academic revenue decreased $21.5 million, or 11%, as compared with the prior year on a reported basis. On a constant currency basis, revenue decreased 9% as compared with the prior year. Excluding revenue from acquisitions, organic revenue decreased 10% on a constant currency basis. This was primarily due to a decrease in Academic Publishing due to a decline in print and digital, partially offset by growth in digital courseware. University Services revenue decreased primarily due to continued online enrollment challenges, and lower fee for service revenue. For the three months ended January 31, 2023, University Services experienced a 4% decline in online enrollment.

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA decreased 20% as compared with the prior year. This decrease was primarily due to the revenue performance.

**University Services Partners and Programs:**

As of January 31, 2023, Wiley had 66 university partners under contract, compared to 64 as of January 31, 2022 within University Services.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **TALENT:** | **2023** | **2023** | **2022** | **2022** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| &nbsp;&nbsp;**Total Talent Revenue** | **$** | **60253** | $| 53525 | 13% | 18% |
| Cost of Sales | **30325** | **30325** | 23884 | 23884 | (27)% | (35)% |
| Operating Expenses | **21400** | **21400** | 20993 | 20993 | (2)% | (6)% |
| Amortization of Intangible Assets | **3213** | **3213** | 2972 | 2972 | (8)% | (11)% |
| Restructuring Charges (Credits) (see Note 9) | **72** | **72** | (41) | (41) | # | # |
| **Contribution to Profit** | **5243** | **5243** | 5717 | 5717 | (8)% | (7)% |
| Restructuring Charges (Credits) (see Note 9) | **72** | **72** | (41) | (41) | # | # |
| **Adjusted Contribution to Profit** | **5315** | **5315** | 5676 | 5676 | (6)% | (5)% |
| Depreciation and amortization | **5458** | **5458** | 5605 | 5605 | 3% | (1)% |
| **Adjusted EBITDA** | **$** | **10773** | $| 11281 | (5)% | (2)% |
| Adjusted EBITDA Margin | **17.9%** | **17.9%** | 21.1% | 21.1% |  |  |

---

# Not meaningful

**Revenue:**

Talent revenue increased $6.7 million, or 13%, as compared with the prior year on a reported basis. On a constant currency basis, revenue increased 18% as compared with the prior year. This was primarily due to double-digit growth in placements and, to a lesser extent, corporate training driving performance. For the three months ended January 31, 2023, we delivered approximately 38% growth in talent placements in talent development (Wiley Edge).

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA decreased 2% as compared with the prior year. This was primarily due to investments to drive scale in talent development (Wiley Edge), and increased inflationary impacts on placements.

**CORPORATE EXPENSES:**

Corporate expenses for the three months ended January 31, 2023 decreased $5.1 million, or 10%, as compared with the prior year. On a constant currency basis, excluding restructuring charges and a legal settlement, these expenses decreased 26%. This was primarily due to lower incentive compensation accrual and, to a lesser extent, reduced technology expenses.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**RESULTS OF OPERATIONS – NINE MONTHS ENDED JANUARY 31, 2023**

**<u>NINE MONTHS SUMMARY:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **US GAAP Results**: Consolidated Revenue of $1,493.8 million (-3%, compared with the prior year), Operating Loss of $(26.6) million (compared with the prior year Operating Income of $160.8 million), Diluted Loss per Share of $(0.92) (compared with the prior year Diluted Earnings per Share of $1.86)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Results** (at constant currency compared with the prior year): Consolidated Revenue of $1,493.8 million (+1%, compared with the prior year), Adjusted EBITDA of $285.2 million (-11%, compared with the prior year), and Adjusted EPS of $2.40 (-23%, compared with the prior year)

**<u>CONSOLIDATED RESULTS OF OPERATIONS</u>**

**Revenue:**

Revenue for the nine months ended January 31, 2023 decreased $43.5 million, or 3%, as compared with the prior year. On a constant currency basis, revenue increased 1% as compared with the prior year including contributions from acquisitions. Excluding the contributions from acquisitions, organic revenue was flat on a constant currency basis.

See the "Segment Operating Results" below for additional details on each segment's revenue and Adjusted EBITDA performance**.**

**Cost of Sales:**

Cost of sales for the nine months ended January 31, 2023 increased $4.7 million, or 1%, as compared with the prior year. On a constant currency basis, cost of sales increased 4% as compared with the prior year. This increase was primarily due to higher employee costs to support the growth in placements in the Talent segment, partially offset by lower royalty costs.

**Operating and Administrative Expenses:**

Operating and administrative expenses for the nine months ended January 31, 2023 decreased $8.7 million, or 1%, as compared with the prior year. On a constant currency basis, operating and administrative expenses increased 3% as compared with the prior year primarily reflecting higher employment costs, travel and entertainment costs and, to a lesser extent, technology costs, and a $3.7 million charge related to the settlement of a litigation matter related to consideration for a previous acquisition in the three months ended January 31, 2023.

**Impairment of Goodwill:**

We recorded an impairment of goodwill for the nine months ended January 31, 2023 of $99.8 million. This charge is reflected in the Impairment of goodwill in the Unaudited Condensed Consolidated Statements of Net (Loss) Income. See above and Note 12, "Goodwill and Intangible Assets" for more details on these charges.

**Restructuring and Related Charges (Credits):**

***Fiscal Year 2023 Restructuring Program***

For the nine months ended January 31, 2023, we recorded pretax restructuring charges of $44.3 million related to this program, which includes $7.5 million related to the closure of our operations in Russia as described above. These charges are reflected in Restructuring and related charges (credits) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. This restructuring charge primarily reflects the following charges:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Severance charges of $24.6 million for the elimination of certain positions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Impairment charges of $12.7 million, which included the impairment of operating lease ROU assets of $7.6 million related to certain leases that will be subleased, and the related property and equipment of $5.1 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acceleration of expense of $2.0 million, which included the acceleration of rent expense associated with operating lease ROU assets of $0.9 million related to certain leases that will be abandoned or terminated and the related depreciation and amortization of property and equipment of $1.1 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ongoing facility-related costs with previously vacated properties that resulted in additional restructuring charges of $3.4 million; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consulting, relocation and other costs of $1.6 million.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

See Note 9, "Restructuring and Related Charges (Credits)" for more details on these charges.

***Business Optimization Program***

For the nine months ended January 31, 2023 and 2022, we recorded pretax restructuring charges of $0.9 million and credits of $1.2 million, respectively, related to this program. These charges and credits are reflected in Restructuring and related charges (credits) on our Unaudited Condensed Consolidated Statements of Net (Loss) Income. See Note 9, "Restructuring and Related Charges (Credits)" for more details on these charges and credits.

For the impact of our restructuring programs on diluted (loss) earnings per share, see the section below, "Diluted (Loss) Earnings per Share (EPS)."

**Amortization of Intangible Assets:**

Amortization of intangible assets was $65.4 million for the nine months ended January 31, 2023, an increase of $1.7 million, or 3%, as compared with the prior year. On a constant currency basis, amortization of intangible assets increased 6% as compared with the prior year primarily due to the acceleration of expense of $4.6 million related to the discontinued use of the mthree trademark and, to a lesser extent, other acquisitions completed in fiscal year 2022 and 2023. These were partially offset by the completion of amortization of certain acquired intangible assets. See Note 3, "Acquisitions" for more details on these acquisitions.

On January 1, 2020, Wiley acquired mthree, a talent placement provider that addresses the IT skills gap by finding, training, and placing job-ready technology talent in roles with leading corporations worldwide. Its results of operations are included in our Talent segment. In late May 2022, Wiley renamed the mthree talent development solution to Wiley Edge and discontinued use of the mthree trademark during the three months ended July 31, 2022. As a result of these actions, we determined that a revision of the useful life was warranted and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.

**Operating (Loss) Income, Adjusted Operating Income (OI) and Adjusted EBITDA:**

Operating loss was $(26.6) million for the nine months ended January 31, 2023 compared with prior year operating income of $160.8 million. The decrease was primarily due to the impairment of goodwill in the three months ended January 31, 2023 as described above and, to a lesser extent, an increase in restructuring charges, operating and administrative expenses, and costs of sales, partially offset by an increase in revenue.

Adjusted OI on a constant currency basis and excluding restructuring charges (credits), impairment of goodwill, legal settlement, and the accelerated amortization of an intangible asset, decreased 22% as compared with the prior year primarily due to an increase in operating and administrative expenses, and cost of sales, partially offset by higher revenues as described above.

Adjusted EBITDA on a constant currency basis and excluding restructuring charges (credits), decreased 11% as compared with the prior year primarily due to a decrease in Adjusted OI.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Adjusted OI***

Below is a reconciliation of our consolidated US GAAP Operating (Loss) Income to Non-GAAP Adjusted OI:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP Operating (Loss) Income** | $**(26582)** | $160845 |
| Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges (credits) | **45204** | (1161) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **99800** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **3671** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accelerated amortization of an intangible asset <sup>(1)</sup> | **4594** |  |
| **Non-GAAP Adjusted OI** | $**126687** | $159684 |

---

(1) As described above, we determined that a revision of the useful life of the mthree trademark was warranted and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.

***Adjusted EBITDA***

Below is a reconciliation of our consolidated US GAAP Net (Loss) Income to Non-GAAP EBITDA and Adjusted EBITDA:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **Net (Loss) Income** | $**(51111)** | $105163 |
| Interest expense | **27185** | 14739 |
| (Benefit) provision for income taxes | **(1397)** | 52673 |
| Depreciation and amortization | **163142** | 162484 |
| **Non-GAAP EBITDA** | **137819** | 335059 |
| Impairment of goodwill | **99800** |  |
| Legal settlement | **3671** |  |
| Restructuring and related charges (credits) | **45204** | (1161) |
| Foreign exchange transaction (gains) losses | **(283)** | 1488 |
| Gain on sale of certain assets | **—** | (3694) |
| Other income, net | **(976)** | (9524) |
| **Non-GAAP Adjusted EBITDA** | $**285235** | $322168 |

---

**Interest Expense:**

Interest expense was $27.2 million for the nine months ended January 31, 2023, compared with the prior year of $14.7 million. This increase was primarily due to a higher weighted average effective interest rate.

**Foreign Exchange Transaction Gains (Losses):**

Foreign exchange transaction gains of $0.3 million for the nine months ended January 31, 2023 were primarily due to gains on our foreign currency denominated third party accounts receivable and payable balances due to the impact of the change in average foreign exchange rates as compared to the US dollar.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Foreign exchange transaction losses of $1.5 million for the nine months ended January 31, 2022 were primarily due to losses on our foreign currency denominated third-party accounts receivable and payable balances due to the impact of the change in average foreign exchange rates as compared to the US dollar.

**Gain on Sale of Certain Assets:**

The gain on the sale of certain assets is due to the sale of our world languages product portfolio which was included in our Academic segment and resulted in a pretax gain of approximately $3.7 million during the nine months ended January 31, 2022.

**Other Income, net**

Other income, net was $1.0 million for the nine months ended January 31, 2023, a decrease of $8.5 million as compared with the prior year. This decrease was primarily due to lower pension income for our defined benefit plans in the nine months ended January 31, 2023.

**(Benefit) Provision for Income Taxes:**

Below is a reconciliation of our US GAAP (Loss) Income Before Taxes to Non-GAAP Adjusted Income Before Taxes:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP (Loss) Income Before Taxes** | $**(52508)** | $157836 |
| Pretax Impact of Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **99800** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **3671** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges (credits) | **45204** | (1161) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions | **906** | 494 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **68611** | 67081 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of certain assets | **—** | (3694) |
| **Non-GAAP Adjusted Income Before Taxes** | $**165684** | $220556 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

Below is a reconciliation of our US GAAP Income Tax (Benefit) Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP Income Tax (Benefit) Provision** | $**(1397)** | $52673 |
| Income Tax Impact of Adjustments <sup>(1)</sup>: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **4857** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **716** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges (credits) | **11159** | (118) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions | **274** | 258 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **14811** | 15097 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of certain assets | **—** | (922) |
| Income Tax Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of increase in UK statutory rate on deferred tax balances <sup>(2)</sup> | **—** | (20726) |
| **Non-GAAP Adjusted Income Tax Provision** | $**30420** | $46262 |
| **US GAAP Effective Tax Rate** | **2.7%** | 33.4% |
| **Non-GAAP Adjusted Effective Tax Rate** | **18.4%** | 21.0% |

---

(1) For the nine months ended January 31, 2023, the tax impact was $5.5 million from current taxes and $26.3 million from deferred taxes. For the nine months ended January 31, 2022, substantially all of the tax impact was from deferred taxes.

(2) These adjustments impacted deferred taxes in the nine months ended January 31, 2022.

Our effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The US GAAP effective tax rate for the nine months ended January 31, 2023 was 2.7% compared to 33.4% for the nine months ended January 31, 2022. The US GAAP effective tax rate for the nine months ended January 31, 2023 was less than the US GAAP effective tax rate for the nine months ended January 31, 2022 after taking into account certain discrete items realized related to the filing of the consolidated US federal income tax return for the year ended April 30, 2022, the tax impact on the impairment of goodwill, as well as the geographic mix of earnings, the impact of US state taxes, and a discrete item relating to restricted stock compensation.

Excluding the tax impact of the impairment of goodwill, restructuring and other adjustments noted in the table above, the Non-GAAP adjusted effective tax rate was 18.4% for the nine months ended January 31, 2023, compared to 21.0% for the nine months ended January 31, 2022. The reduction in the Non-GAAP adjusted effective tax rate for the nine months ended January 31, 2023 compared with the prior year was primarily due to the same factors described above.

**Diluted (Loss) Earnings per Share (EPS):**

EPS for the nine months ended January 31, 2023 was a loss of $(0.92) per share compared with earnings of $1.86 per share for the nine months ended January 31, 2022. This decrease was due to an operating loss in the nine months ended January 31, 2023 and, to a lesser extent, higher interest expense, lower pension income, and the gain on sale of certain assets in the prior year, partially offset by an income tax benefit in the nine months ended January 31, 2023.

Below is a reconciliation of our US GAAP (Loss) Earnings Per Share to Non-GAAP Adjusted EPS. The amount of the pretax, and the related income tax impact for the adjustments included in the table below, are presented in the section above, "(Benefit) Provision for Income Taxes".

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **US GAAP (Loss) Earnings Per Share** | $**(0.92)** | $1.86 |
| <u>Adjustments:</u> |  |  |
| &nbsp;&nbsp;&nbsp;Impairment of goodwill | **1.69** |  |
| &nbsp;&nbsp;&nbsp;Legal settlement | **0.05** |  |
| &nbsp;&nbsp;&nbsp;Restructuring and related charges (credits) | **0.60** | (0.02) |
| &nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions | **0.01** |  |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | **0.96** | 0.93 |
| &nbsp;&nbsp;&nbsp;Gain on sale of certain assets | **—** | (0.05) |
| &nbsp;&nbsp;&nbsp;Income tax adjustments | **—** | 0.37 |
| &nbsp;&nbsp;&nbsp;EPS impact of using weighted-average dilutive shares for adjusted EPS calculation <sup>(1)</sup> | **0.01** |  |
| **Non-GAAP Adjusted EPS** | $**2.40** | $3.09 |

---

(1) Represents the impact of using diluted weighted-average number of common shares outstanding (56.3 million shares for the nine months ended January 31, 2023) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive.

On a constant currency basis, Adjusted EPS decreased 23% primarily due to a lower Adjusted OI and, to a lesser extent, an increase in interest expense, and lower pension income, partially offset by lower income tax expense.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**<u>SEGMENT OPERATING RESULTS</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **RESEARCH:** | **2023** | **2022** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **Revenue:** |  |  |  |  |
| Research Publishing <sup>(1)</sup> | $**685884** | $706690 | (3)% | 1% |
| Research Solutions <sup>(1)</sup> | **113988** | 106561 | 7% | 11% |
| &nbsp;&nbsp;**Total Research Revenue** | **799872** | 813251 | (2)% | 2% |
| Cost of Sales | **213108** | 218369 | 2% | (1)% |
| Operating Expenses | **351016** | 341084 | (3)% | (8)% |
| Amortization of Intangible Assets | **35009** | 35556 | 2% | (3)% |
| Restructuring Charges (see Note 9) | **1577** | 238 | # | # |
| **Contribution to Profit** | **199162** | 218004 | (9)% | (8)% |
| Restructuring Charges (see Note 9) | **1577** | 238 | # | # |
| **Adjusted Contribution to Profit** | **200739** | 218242 | (8)% | (7)% |
| Depreciation and amortization | **70308** | 71140 | 1% | (2)% |
| **Adjusted EBITDA** | $**271047** | $289382 | (6)% | (5)% |
| Adjusted EBITDA Margin | **33.9%** | 35.6% |  |  |

---

# Not meaningful

(1) As previously announced in May 2022, our revenue by product type previously referred to as Research Platforms was changed to Research Solutions. Research Solutions includes infrastructure and publishing services that help societies and corporations thrive in a complex knowledge ecosystem. In addition to Platforms (Atypon), certain product offerings such as corporate sales which included the recent acquisitions of Madgex Holdings Limited (Madgex), and Bio-Rad Laboratories Inc.'s Informatics products (Informatics) that were previously included in Research Publishing moved to Research Solutions to align with our strategic focus. Research Solutions also includes product offerings related to certain recent acquisitions such as J&J, and EJP. Prior period results have been revised to the new presentation. There were no changes to the total Research segment or our consolidated financial results. The revenue reclassified was $68.4 million for the nine months ended January 31, 2022, $93.3 million for the year ended April 30, 2022, and $80.3 million for the year ended April 30, 2021.

**Revenue:**

Research revenue for the nine months ended January 31, 2023 decreased $13.4 million, or 2%, as compared with the prior year on a reported basis. On a constant currency basis, revenue increased 2% as compared with the prior year. Excluding revenue from acquisitions, organic revenue increased 1% on a constant currency basis. This increase was primarily due to an increase in open access publishing, partially offset by subscriptions. As described above in the three months ended January 31, 2023, open access was impacted by the publishing pause in a Hindawi special issues program. Open access article output growth was approximately 11% for the nine months ended January 31, 2023, as compared with the prior year.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA decreased 5% as compared with the prior year. This decrease was primarily due to investments to optimize and scale publishing and solutions and, to a lesser extent, higher employment costs, and travel and entertainment costs due to the resumption of in-person activities, which more than offset the increase in revenue.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **ACADEMIC:** | **2023** | **2022** | **% Change<br>Favorable<br>(Unfavorable)** | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **Revenue:** |  |  |  |  |
| Academic Publishing | $**354728** | $400740 | (11)% | (9)% |
| University Services | **152892** | 169002 | (10)% | (9)% |
| &nbsp;&nbsp;&nbsp;**Total Academic Revenue** | **507620** | 569742 | (11)% | (9)% |
| Cost of Sales | **215344** | 230985 | 7% | 5% |
| Operating Expenses | **243084** | 250798 | 3% | —% |
| Impairment of Goodwill (see Note 12) | **99800** |  | # | # |
| Amortization of Intangible Assets | **17700** | 19131 | 7% | 7% |
| Restructuring Charges (Credits) (see Note 9) | **10091** | (347) | # | # |
| **Contribution to Profit** | **(78399)** | 69175 | # | # |
| Restructuring Charges (Credits) (see Note 9) | **10091** | (347) | # | # |
| Impairment of Goodwill (see Note 12) | **99800** |  | # | # |
| **Adjusted Contribution to Profit** | **31492** | 68828 | (54)% | (52)% |
| Depreciation and amortization | **61547** | 61622 | —% | (1)% |
| **Adjusted EBITDA** | $**93039** | $130450 | (29)% | (27)% |
| Adjusted EBITDA Margin | **18.3%** | 22.9% |  |  |

---

# Not meaningful

**Revenue:**

Academic revenue decreased $62.1 million, or 11%, as compared with the prior year on a reported basis. On a constant currency basis, revenue decreased 9% as compared with the prior year. Excluding revenue from acquisitions, organic revenue decreased 10% on a constant currency basis. This decrease was primarily due a decrease in Academic Publishing due to a decline in print and digital, partially offset by an increase in courseware. University Services revenue decreased primarily due to continued online enrollment challenges and lower fee for service revenue.

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA decreased 27% as compared with the prior year. This decrease was primarily due to lower revenues and, to a lesser extent, inflationary impacts on inventory, higher technology and distribution costs, partially offset by expense savings, and lower annual incentive compensation.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| **TALENT:** | **2023** | **2022** | **% Change**<br>**Favorable**<br>**(Unfavorable)**  | **Constant Currency** <br>**% Change**<br>**Favorable**<br>**(Unfavorable)**  |
| &nbsp;&nbsp;**Total Talent Revenue** | $**186281** | $154282 | 21% | 28% |
| Cost of Sales | **89932** | 64300 | (40)% | (51)% |
| Operating Expenses | **63502** | 64371 | 1% | (5)% |
| Amortization of Intangible Assets | **12559** | 8996 | (40)% | (43)% |
| Restructuring Charges (see Note 9) | **2400** | 245 | # | # |
| **Contribution to Profit** | **17888** | 16370 | 9% | 13% |
| Restructuring Charges (see Note 9) | **2400** | 245 | # | # |
| Accelerated amortization of an intangible asset <sup>(1)</sup> | **4594** |  | # | # |
| **Adjusted Contribution to Profit** | **24882** | 16615 | 50% | 53% |
| Depreciation and amortization | **14688** | 17304 | 15% | 9% |
| **Adjusted EBITDA** | $**39570** | $33919 | 17% | 21% |
| Adjusted EBITDA Margin | **21.2%** | 22.0% |  |  |

---

# Not meaningful

(1) On January 1, 2020, Wiley acquired mthree, a talent placement provider that addresses the IT skills gap by finding, training, and placing job-ready technology talent in roles with leading corporations worldwide. Its results of operations are included in our Talent segment. In late May 2022, Wiley renamed the mthree talent development solution to Wiley Edge and discontinued use of the mthree trademark during the three months ended July 31, 2022. As a result of these actions, we determined that a revision of the useful life was warranted, and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.

**Revenue:**

Talent revenue increased $32.0 million, or 21%, as compared with the prior year on a reported basis. On a constant currency basis, revenue increased 28% as compared with the prior year. This was primarily due to double-digit growth in placements and, to a lesser extent, an increase in corporate training. For the nine months ended January 31, 2023, we delivered approximately 38% growth in talent placements in talent development (Wiley Edge).

**Adjusted EBITDA:**

On a constant currency basis, Adjusted EBITDA increased 21% as compared with the prior year. This was primarily due to revenue, partially offset by increased inflationary impacts on placements and, to drive scale in talent development (Wiley Edge)

**CORPORATE EXPENSES:**

Corporate expenses for the nine months ended January 31, 2023 increased $22.5 million, or 16%, as compared with the prior year. On a constant currency basis and excluding restructuring (credits) charges and a legal settlement, these expenses decreased 5% as compared with the prior year. This was primarily due to lower employee related costs, including lower annual incentive compensation for fiscal year 2023.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**FISCAL YEAR 2023 OUTLOOK:**

Wiley is reducing its financial outlook at constant currency:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue:** downward revision by an additional $45 million to $60 million primarily due to increased Academic market headwinds and the publishing pause in Hindawi special issues which is projected to impact revenue up to $30 million and Adjusted EBITDA up to $25 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted EBITDA:** downward revision by $30 million to $40 million due to lower projected revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted EPS:** downward revision by 40 cents to 50 cents due to lower projected Adjusted EBITDA and higher interest expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Free Cash Flow:** downward revision primarily due to lower projected cash earnings and higher restructuring payments, mainly related to the closing of Wiley's Russia tech development center. Our capital expenditure range remains at $110 million to $120 million.

*Amounts in millions, except Adjusted EPS*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Metric | **Fiscal Year 2022**<br>**Actual** <sup>(1)</sup> | **Fiscal Year 2023 Outlook** <br>Constant currency<br>**Previous** <sup>(1)</sup> | **Fiscal Year 2023 Outlook**<br>Constant currency<br>**Current** <sup>(1)</sup> | **Foreign Currency Impact** <sup>(2)</sup> | **Fiscal Year 2023 Outlook** <br>Year to date average rates<br>**Current** <sup>(3)</sup> |
| **Revenue** | $2083 | $2110 - $2150 | $2065 - $2090 | $(60) | $2005 - $2030 |
| **Adjusted EBITDA** | $433 | $425 - $450 | $395 - $410 | Immaterial | $395 - $410 |
| **Adjusted EPS** | $4.16 | $3.70 - $4.05 | $3.30 - $3.55 | Immaterial | $3.30 - $3.55 |
| **Free Cash Flow** | $223 | $210 - $235 | $160 - $185 | Immaterial | $160 - $185 |

---

(1) Based on fiscal year 2022 average rates of 1.15 euro and 1.36 British pound.

(2) Variance between fiscal year 2022 average rates and year to date fiscal year 2023 average rates.

(3) Fiscal year 2023 outlook at average year to date rates of 1.04 euro and 1.20 British pound.

In August 2022, the White House Office of Science and Technology Policy (OSTP) issued guidance for US federal agencies to make federally funded research freely available starting no later than December 31, 2025, without an embargo. For reference, approximately 11% of Wiley's published articles today are funded by US federal departments impacted by this guidance, and a third of those articles are already open access. Wiley has been working for several years with the OSTP and other stakeholders around the world to support the orderly transition to open research. This new guidance is aligned with Wiley's stated strategy and mission, and is supported by the growth the Company is seeing in open research publishing. Wiley supports multiple publishing models to execute against the industry's shared objective of unlocking access to scientific research and improving the efficiency of peer review and publication. Those models include journal subscriptions ("pay to read"), transformational agreements ("pay to read and publish") and open access ("pay to publish"). In the past three years, our open access revenues, including from transformational agreements, have increased from less than 6% of total Research Publishing revenues to approximately 32% today. Based on our assessment of the guidance, we do not believe it will have a material financial impact on our Company.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**LIQUIDITY AND CAPITAL RESOURCES**

**Principal Sources of Liquidity**

We believe that our operating cash flow, together with our revolving credit facilities and other available debt financing, will be adequate to meet our operating, investing and financing needs in the foreseeable future. There can be no assurance that continued or increased volatility in the global capital and credit markets will not impair our ability to access these markets on terms commercially acceptable in the future. We do not have any off-balance-sheet debt. We will continue to pursue attractive opportunities to add scale and provide enhanced technology-enabled services in research and online education.

As of January 31, 2023, we had cash and cash equivalents of $126.4 million, of which approximately $119.8 million, or 95%, was located outside the US. Maintenance of these cash and cash equivalent balances outside the US does not have a material impact on the liquidity or capital resources of our operations. Nonetheless, we intend to repatriate earnings from our non-US subsidiaries, and as we repatriate these funds to the US, we will be required to pay income taxes in various US state and local jurisdictions, and applicable withholding or similar taxes in the periods in which such repatriation occurs. Accordingly, as of January 31, 2023, we have an approximately $2.7 million liability related to the estimated taxes that would be incurred upon repatriating certain non-US earnings.

On November 30, 2022, we entered into the second amendment to the Third Amended and Restated Credit Agreement (collectively, the Amended and Restated CA). The Amended and Restated CA as of November 30, 2022 provided for senior unsecured credit facilities comprised of a (i) five-year revolving credit facility in an aggregate principal amount up to $1.115 billion, (ii) a five-year term loan A facility consisting of $200 million, and (iii) $185 million aggregate principal amount revolving credit facility through May 2024. See Note 15, "Debt and Available Credit Facilities" for further details on the Amended and Restated CA.

As of January 31, 2023, we had approximately $945.6 million of debt outstanding, net of unamortized issuance costs of $0.8 million, and approximately $553.4 million of unused borrowing capacity under our Amended and Restated CA and other facilities. The Amended and Restated CA contains certain customary affirmative and negative covenants, including a financial covenant in the form of a consolidated net leverage ratio and consolidated interest coverage ratio, which we were in compliance with as of January 31, 2023.

**Analysis of Historical Cash Flows**

The following table shows the changes in our Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended January 31, 2023 and 2022.

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| Net cash provided by operating activities | $**53718** | $158484 |
| Net cash used in investing activities | **(80072)** | (152051) |
| Net cash provided by financing activities | **55284** | 13099 |
| Effect of foreign currency exchange rate changes on cash, cash equivalents and restricted cash | $**(2670)** | $(3875) |

---

Cash flow from operations is seasonally a use of cash in the first half of Wiley's fiscal year principally due to the timing of collections for annual journal subscriptions, which typically occurs in the beginning of the second half of our fiscal year.

Free cash flow less product development spending helps assess our ability, over the long term, to create value for our shareholders, as it represents cash available to repay debt, pay common dividends, and fund share repurchases, and acquisitions. Below are the details of Free cash flow less product development spending.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Free Cash Flow less Product Development Spending:***

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2023** | **2022** |
| **Net cash provided by operating activities** | $**53718** | $158484 |
| Less: Additions to technology, property and equipment | **(57616)** | (60668) |
| Less: Product development spending | **(17763)** | (20388) |
| **Free cash flow less product development spending** | $**(21661)** | $77428 |

---

***Net Cash Provided by Operating Activities***

The following is a summary of the $104.8 million change in Net cash provided by operating activities for the nine months ended January 31, 2023 compared with the nine months ended January 31, 2022 (amounts in millions).

---

| | |
|:---|:---|
| **Net cash provided by operating activities – Nine months ended January 31, 2022** | $158.5 |
| Net (loss) income adjusted for items to reconcile net (loss) income to net cash provided by operating activities, which would include such noncash items as, depreciation and amortization, and the change in deferred taxes | (53.5) |
| <u>Working capital changes:</u> |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net and contract liabilities | 19.4 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued royalties | (27.9) |
| &nbsp;&nbsp;&nbsp;Changes in other assets and liabilities | (42.8) |
| **Net cash provided by operating activities – Nine months ended January 31, 2023** | $**53.7** |

---

The favorable change in accounts receivable, net and contract liabilities was primarily due to the timing of collections with customers.

The unfavorable change in accounts payable and accrued royalties was primarily due to the timing of payments.

The unfavorable changes in other assets and liabilities noted in the table above was primarily due to higher restructuring payments in fiscal year 2023, lower employee related costs due to lower annual incentive compensation for fiscal year 2023, and the timing of prepayments and other receivables.

Wiley expects working capital timing to largely resolve in the fourth quarter of fiscal year 2023.

Our negative working capital (current assets less current liabilities) was $229.8 million and $418.6 million as of January 31, 2023 and April 30, 2022, respectively. This $188.8 million change in negative working capital was primarily due to the seasonality of our business. The primary driver of the negative working capital is the benefit realized from unearned contract liabilities related to subscriptions for which cash has been collected in advance. The contract liabilities will be recognized as income when the products are shipped or made available online to the customers over the term of the subscription. Current liabilities as of January 31, 2023 and as of April 30, 2022 includes $369.3 million and $538.1 million, respectively, primarily related to deferred subscription revenue for which cash was collected in advance.

Cash collected in advance for subscriptions is used by us for a number of purposes, including funding operations, capital expenditures, acquisitions, debt repayments, dividend payments, and share repurchases.

***Net Cash Used In Investing Activities***

Net cash used in investing activities for the nine months ended January 31, 2023 was $80.1 million compared to $152.1 million in the prior year. The decrease in cash used in investing activities was primarily due to a decrease of $64.8 million in cash used to acquire businesses.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

***Net Cash Provided By Financing Activities***

Net cash provided by financing activities was $55.3 million for the nine months ended January 31, 2023 compared to $13.1 million for the nine months ended January 31, 2022. This increase in cash provided by financing activities was primarily due to an increase in net borrowings of long-term debt of $57.0 million, partially offset by a change in book overdrafts of $11.0 million.

In the nine months ended January 31, 2023, we increased our quarterly dividend to shareholders to $1.39 per share annualized versus $1.38 per share annualized in the prior year.

The following table summarizes the shares repurchased of Class A and Class B Common Stock for the nine months ended January 31, 2023 and 2022 (shares in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2022** | **2021** |
| Shares repurchased – Class A | **539** | 446 |
| Shares repurchased – Class B | **1** | 2 |
| Average price – Class A and Class B | $**44.47** | $55.48 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to market risk primarily related to interest rates, foreign exchange, and credit risk. It is our policy to monitor these exposures and to use derivative financial investments and/or insurance contracts from time to time to reduce fluctuations in earnings and cash flows when it is deemed appropriate to do so. We do not use derivative financial instruments for trading or speculative purposes.

**Interest Rates**

From time to time, we may use interest rate swaps, collars, or options to manage our exposure to fluctuations in interest rates. It is management's intention that the notional amount of interest rate swaps be less than the variable rate loans outstanding during the life of the derivatives.

The information set forth in Note 16, "Derivatives Instruments and Hedging Activities," of the Notes to Unaudited Condensed Consolidated Financial Statements under the caption "Interest Rate Contracts," is incorporated herein by reference.

On an annual basis, a hypothetical one percent change in interest rates for the $495.6 million of unhedged variable rate debt as of January 31, 2023 would affect net income and cash flow by approximately $4.0 million.

**Foreign Exchange Rates**

Fluctuations in the currencies of countries where we operate outside the US may have a significant impact on financial results. We are primarily exposed to movements in British pound sterling, euros, Canadian and Australian dollars, and certain currencies in Asia. The statements of financial position of non-US business units are translated into US dollars using period-end exchange rates for assets and liabilities and the statements of income are translated into US dollars using weighted-average exchange rates for revenues and expenses.

Our significant investments in non-US businesses are exposed to foreign currency risk. Adjustments resulting from translating assets and liabilities are reported as a separate component of Accumulated other comprehensive loss, net of tax within Shareholders' Equity under the caption Foreign currency translation adjustment. During the three months ended January 31, 2023, we recorded foreign currency translation gains in Accumulated other comprehensive loss, net of tax of approximately $50.3 million, primarily as a result of the fluctuations of the US dollar relative to the British pound sterling and, to a lesser extent, the euro. During the nine months ended January 31, 2023, we recorded foreign currency translation (losses) in Accumulated other comprehensive loss, net of tax of approximately $(5.6) million, primarily as a result of the fluctuations of the US dollar relative to the British pound sterling, partially offset by fluctuations of the US dollar relative to the euro. During the three and nine months ended January 31, 2022, we recorded foreign currency translation losses in Accumulated other comprehensive loss, net of tax of approximately $(15.9) million and $(31.3) million, respectively, primarily as a result of the fluctuations of the US dollar relative to the euro and the British pound sterling.

Exchange rate gains or losses related to foreign currency transactions are recognized as transaction gains or losses on the Unaudited Condensed Consolidated Statements of Net (Loss) Income as incurred. Under certain circumstances, we may enter into derivative financial instruments in the form of foreign currency forward contracts to hedge against specific transactions, including intercompany purchases and loans.

The information set forth in Note 16, "Derivatives Instruments and Hedging Activities," of the Notes to Unaudited Condensed Consolidated Financial Statements under the caption "Foreign Currency Contracts," is incorporated herein by reference.

**Sales Return Reserves**

The estimated allowance for print book sales returns is based upon historical return patterns, as well as current market trends in the businesses in which we operate. In connection with the estimated sales return reserves, we also include a related increase to inventory and a reduction to accrued royalties as a result of the expected returns.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

The reserves are reflected in the following accounts of our Unaudited Condensed Consolidated Statements of Financial Position:

---

| | | |
|:---|:---|:---|
| | **January 31, 2023** | **April 30, 2022** |
| Increase in Inventories, net | $**7378** | $7820 |
| Decrease in Accrued royalties | $**(3678)** | $(3893) |
| Increase in Contract liabilities | $**27974** | $31135 |
| Print book sales return reserve net liability balance | $**(16918)** | $(19422) |

---

A one percent change in the estimated sales return rate could affect net income by approximately $0.4 million. A change in the pattern or trends in returns could affect the estimated allowance.

**Customer Credit Risk**

In the journal publishing business, subscriptions are primarily sourced through journal subscription agents who, acting as agents for library customers, facilitate ordering by consolidating the subscription orders/billings of each subscriber with various publishers. Cash is generally collected in advance from subscribers by the subscription agents and is principally remitted to us between the months of December and April. Although currently we have minimal credit risk exposure to these agents, future calendar-year subscription receipts from these agents are highly dependent on their financial condition and liquidity. Subscription agents account for approximately 20% of total annual consolidated revenue, and no one affiliated group of subscription agents accounts for more than 10% of total annual consolidated revenue.

Our book business is not dependent upon a single customer; however, the industry is concentrated in national, regional, and online bookstore chains. No single book customer accounts for more than 7% of total consolidated revenue and more than 14% of accounts receivable at January 31, 2023. The top 10 book customers account for approximately 11% of total consolidated revenue and approximately 24% of accounts receivable at January 31, 2023.

**ITEM 4. CONTROLS AND PROCEDURES**

The Company's Chief Executive Officer and Chief Financial Officer, together with the Chief Accounting Officer and other members of the Company's management, have conducted an evaluation of the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission's rules and forms and (ii) accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the quarter ended January 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

There have been no significant developments related to legal proceedings during the three months ended January 31, 2023. For information regarding legal proceedings, see our Annual Report on Form 10-K for the fiscal year ended April 30, 2022 Note 16, "Commitment and Contingencies".

**ITEM 1A. RISK FACTORS**

See Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended April 30, 2022. Except as required by the federal securities law, we undertake no obligation to update or revise any risk factor, whether as a result of new information, future events or otherwise.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

During the three months ended January 31, 2023, we made the following purchases of Class A and Class B Common Stock under our publicly announced stock repurchase programs:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total Number<br>of Shares<br>Purchased** | **Average<br>Price Paid<br>Per Share** | **Total Number<br>of Shares Purchased<br>as part of a Publicly<br>Announced Program** | **Maximum Number<br>of Shares that May<br>be Purchased<br>Under the Program** | **Maximum Dollar<br>Value of Shares<br>that May be Purchased<br>Under Additional Plans<br> or Programs<br>(Dollars in millions)** |
| November 2022 |  | $— |  |  | $180.0 |
| December 2022 | 93909 | 40.08 | 93909 |  | 176.2 |
| January 2023 | 64077 | 42.71 | 64077 |  | 173.5 |
| **Total** | 157986 | $41.14 | 157986 |  | $173.5 |

---

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Material Contracts** | **Material Contracts** |
| **Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002** | **Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002** |
| <u>[31.1\*](wly-2023131xexx311.htm)</u> | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| <u>[31.2\*](wly-2023131xexx312.htm)</u> | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| **Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** | **Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** |
| <u>[32.1\*](wly-2023131xexx321.htm)</u> | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| <u>[32.2\*](wly-2023131xexx322.htm)</u> | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| **Inline XBRL** | **Inline XBRL** |
| **101.INS\*** | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| **101.SCH\*** | Inline XBRL Taxonomy Extension Schema Document. |
| **101.CAL\*** | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| **101.DEF\*** | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| **101.LAB\*** | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| **101.PRE\*** | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| **104** | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

\*Filed herewith

------

<u>[INDEX](#ic0b42a4fbc1943749f60782842ce8f12_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| | **JOHN WILEY & SONS, INC.**<br>Registrant |
| By | /s/ Brian A. Napack |
|  | Brian A. Napack |
|  | President and Chief Executive Officer |
| By | /s/ Christina Van Tassell |
|  | Christina Van Tassell |
|  | Executive Vice President and Chief Financial Officer |
| By | /s/ Christopher F. Caridi |
|  | Christopher F. Caridi |
|  | Senior Vice President, Global Corporate Controller and Chief Accounting Officer |
|  | Dated: March 10, 2023 |

---

## Exhibit 31.1

**Exhibit 31.1**

**<u>CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</u>**

I, Brian A. Napack, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of John Wiley & Sons, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclose controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ Brian A. Napack |
|  | Brian A. Napack |
|  | President and Chief Executive Officer |
|  | Dated: March 10, 2023 |

---

## Exhibit 31.2

**Exhibit 31.2**

**<u>CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</u>**

I, Christina Van Tassell, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of John Wiley & Sons, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ Christina Van Tassell |
|  | Christina Van Tassell |
|  | Executive Vice President and Chief Financial Officer |
|  | Dated: March 10, 2023 |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of John Wiley & Sons, Inc. (the "Company") on Form 10-Q for the period ended January 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brian A. Napack, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Brian A. Napack |
|  | Brian A. Napack |
|  | President and Chief Executive Officer |
|  | Dated: March 10, 2023 |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of John Wiley & Sons, Inc. (the "Company") on Form 10-Q for the period ended January 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christina Van Tassell, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Christina Van Tassell |
|  | Christina Van Tassell |
|  | Executive Vice President and Chief Financial Officer |
|  | Dated: March 10, 2023 |

---

<br>